Studie 032 (M2020/0032)

Studienbericht

PNU-155950E Study Report for M/2020/0032 a0098197 19 November 2001

REBOXETINE (PNU-155950E) VS FLUOXETINE IN A DOUBLE-BLIND STUDY FOR THE TREATMENT OF MAJOR DEPRESSIVE DISORDERS IN TAIWAN.

Project Code:	PHA-950E-CNS-0005
Final Report of the Study:	M/2020/0032
Previous Reports of the Study:	None
Date of First Subject Enrolled:	31 August 2000
Date of Last Subject Enrolled:	31 May 2001
Date of Last Follow-up:	20 July 2001
Coordinating Investigator:	Ming-Been Lee, MD Chairman, Department of Psychiatry; Professor, National Taiwan University Hospital 7 Chung-Shan S. Rd. Taipei 100, Taiwan, R.O.C.
Sponsor's Responsible Medical Officer:	Mark T. Brown, MD Medical Development Therapeutic Area CNS
Development Phase of Study:	3

It is the policy of Pharmacia to conduct clinical studies (including study conduct and the archiving of essential documents) in compliance with company SOPs and Standard, which incorporate the requirements of the ICH Guideline for Good Clinical Practice.

This document contains confidential information belonging to Pharmacia. Except as may be otherwise agreed to in writing, by accepting or reviewing these materials, you agree to hold such information in confidence and not to disclose it to others (except where required by applicable law), nor to use it for unauthorized purposes. In the event of actual or suspected breach of this obligation, Pharmacia should be promptly notified.

Pharmacia — Company Confidential Page 1 of 342

PNU-155950E	a0098197
Study Report for M/2020/0032	19 November 2001

REBOXETINE (PNU-155950E) VS FLUOXETINE IN A DOUBLE-BLIND STUDY FOR THE TREATMENT OF MAJOR DEPRESSIVE DISORDERS IN TAIWAN

APPROVAL SIGNATURES

I have read the report and confirm that to the best of my knowledge it accurately describes the conduct and results of the study.

Mark T. Brown, MD, Clinical Program Director Medical Development, Therapeutic Area CNS Pharmacia & Upjohn, Kalamazoo, MI, USA	Date
Christopher C. Gallen, MD, PhD, Therapeutic Area Vice President Medical Development, Therapeutic Area CNS Pharmacia & Upjohn, Kalamazoo, MI, USA	Date
Scott E. Lancaster, MS, Statistician Clinical Biostatistics Pharmacia & Upjohn, Kalamazoo, MI, USA	Date
Julie A. Wagner, RN, BS, Clinical Research Specialist Medical Development, Therapeutic Area CNS Pharmacia & Upjohn, Kalamazoo, MI, USA	Date
Gary L. Neff, MS, Clinical Research Specialist Medical Development, Therapeutic Area CNS Pharmacia & Upjohn, Kalamazoo, MI, USA	Date
Clayton R. Rowland, PhD, Program Director Outcomes Research Pharmacia & Upjohn, Kalamazoo, MI, USA	Date

Pharmacia — Company Confidential Page 2 of 342

PNU-155950E Study Report for M/2020/0032 a0098197 19 November 2001

The approval signature of the coordinating investigator is in Appendix 1.13.

Pharmacia — Company Confidential Page 3 of 342

PNU-155950E Study Report for M/2020/0032	a0098197 19 November 2001
SYNOPSIS	
Name of Company: Pharmacia	(For National Authority Use only)
Name of Finished Product: (To be assigned)	
Name of Active Ingredient: Reboxetine mesylate	
Title of Study: Reboxetine (PNU-155950E) vs Fluoxetine in a D Major Depressive Disorders in Taiwan	Double-Blind Study for the Treatment of
Protocol Number: M/2020/0032	
Investigators and Study Centers: This multicenter study was convestigators at 5 study centers in Taiwan: Mei-Chih Tseng (Nati Shih-Ku Lin (Taipei City Psychiatric Center), Ying-Chiao Lee (V Chiu (Chang-Gung Memorial Hospital, Kaohsiung), and Ru-Band Publication Reference: none	onal Taiwan University Hospital, Taipei), Veterans General Hospital Taipei), Nien-Mu
Studied Period:	Phase of Development: 3
Studied Feriod.Date of first subject enrolled:31 August 2000Date of last subject enrolled:31 May 2001Date of last follow-up:20 July 2001	Thase of Development. 5
Objectives: Primary: The primary objective of this study was to compare the (administered at a dose of 8 to 10 mg/day for 8 weeks) with that of 40 mg/day for 8 weeks), as measured by the change from baseline Depression (HAM-D) total score at the last assessment in patients (MDD).	of fluoxetine (administered at a dose of 20 to e in the 21-Item Hamilton Rating Scale for
Secondary: The secondary efficacy objective of this study was to (administered at a dose of 8 to 10 mg/day for 8 weeks) with that of 40 mg/day for 8 weeks), as measured by the change from baseline Scale (SASS) total score and in the Clinical Global Impression (C suffering from MDD.	of fluoxetine (administered at a dose of 20 to e in the Social Adaptation Self-evaluation
The safety objective of this study was to compare the tolerability laboratory tests, and electrocardiograms [ECGs]) of reboxetine (a weeks) with that of fluoxetine (administered at a dose of 20 to 40 from MDD.	administered at a dose of 8 to 10 mg/day for 8

Pharmacia — Company Confidential Page 4 of 342

PNU-155950E	a0098197
Study Report for M/2020/0032	19 November 2001
Name of Company:	(For National Authority Use only)

Pharmacia	(For National Autority Ose only)
Name of Finished Product: (To be assigned)	
Name of Active Ingredient: Reboxetine mesylate	

Methodology: This phase III, multicenter, randomized, double-blind, active-controlled, parallel-group study was conducted in 85 patients aged 18 to 65 years who suffered from MDD without psychotic features, as diagnosed using criteria defined by the Diagnostic and Statistical Manual of Mental Disorders—Fourth Edition (DSM-IV).

The patients were selected from a population of patients who were hospitalized or were receiving care at outpatient or day-hospital clinics. Patients who had a score of ≥ 22 on the 21-Item HAM-D at the screening and baseline visit and who met the other eligibility criteria were randomized to receive 8 weeks of treatment with reboxetine (8 mg/day, days 1-28; 8-10 mg/day, days 29-56), or fluoxetine (20 mg/day, days 1-28; 20-40 mg/day, days 29-56). The optional dose increase to 10 mg/day of reboxetine or 40 mg/day of fluoxetine was allowed after 4 weeks of therapy in those patients whom the investigator believed would benefit in terms of response and would adequately tolerate the increased dose. Study visits were conducted weekly during the first 4 weeks of treatment and every 2 weeks during the last 4 weeks of treatment. Efficacy measures and certain safety measures (adverse events and vital signs) were assessed at each visit (days 0, 7, 14, 21, 28, 42, and 56); laboratory tests and ECGs were measured at screen, day 28, and day 56.

Number of Subjects (Planned and Analyzed): The planned enrollment in the study was 80 patients (40 patients in each treatment group). The actual enrollment was 85 patients (43 patients in the reboxetine group and 42 patients in the fluoxetine group). All of the randomized patients received at least 1 dose of study medication. Therefore, the intent-to-treat (ITT) population includes 43 reboxetine-treated patients and 42 fluoxetine-treated patients.

Diagnosis and Main Criteria for Inclusion: Patients of either sex, aged 18 to 65 years, who had a diagnosis of MDD without psychotic features (as defined by DSM-IV) and a total score of \geq 22 on the 21-Item HAM-D were enrolled in the study. Patients were otherwise healthy and had no other significant psychiatric condition.

Test Product, Dose and Mode of Administration, Batch Number:

Reboxetine mesylate tablets (4-mg tablet or 1/2 of a 4-mg tablet) were inserted into gelatin capsules for use in this randomized study. During weeks 1 through 4, reboxetine was administered orally in twice-daily doses of 4 mg (lot number 00427.05), for a total daily dose of 8 mg of reboxetine. After 4 weeks of treatment, the reboxetine dose was increased to 10 mg/day by including a placebo capsule (lot number 00427.03) with the morning dose (to maintain the study blind) and a 2-mg capsule of reboxetine (lot number 00427.06) with the late afternoon dose in patients whom the investigator believed would benefit in terms of response and would adequately tolerate the increased dose.

Duration of Treatment: 8 weeks

Pharmacia — Company Confidential Page 5 of 342

PNU-155950E	a0098197
Study Report for M/2020/0032	19 November 2001
Name of Company:	(For National Authority Use only)
Pharmacia	
Name of Finished Product:	

Reference Therapy, Dose and Mode of Administration, Batch Number: The fluoxetine (ProzacTM, Eli Lilly and Company, Indianapolis, IN) comparator was commercially available and was inserted into gelatin capsules by Pharmacia & Upjohn (Pharmacia).

During weeks 1 through 4, a 20-mg capsule of fluoxetine (lot number 00427.04) was administered orally, once daily, in the morning. After 4 weeks of treatment, the fluoxetine dose was increased to 40 mg/day by including a second 20-mg capsule (lot number 00427.04) with the morning dose in patients whom the investigator believed would benefit in terms of response and would adequately tolerate the increased dose. Placebo capsules (lot number 00427.03) were administered in the late afternoon to maintain the study blind.

During the placebo washout period, a placebo tablet (lot number H06A02) was administered orally, once daily.

Endpoints and Criteria for Evaluation:

Efficacy: The primary endpoint was the change from baseline in the HAM-D total score at the last assessment. The secondary efficacy endpoints included both continuous measures of efficacy, such as the mean change from baseline in the CGI Severity of Illness score and in the total score for the SASS, and categorical measures of efficacy, including the HAM-D response rate, the HAM-D remission rate, the CGI Global Improvement score, and the CGI Global Improvement response rate.

Safety: The secondary safety endpoints were adverse events, vital signs, safety laboratory tests, and ECGs. Adverse events and vital signs were assessed at each postbaseline visit. Safety laboratory tests and ECGs were obtained at screen, day 28, and day 56.

Statistical Methods:

(To be assigned)

Name of Active Ingredient: Reboxetine mesylate

The ITT population, which includes all patients who were randomized into the trial and who received at least one dose of study medication, was used for all of the analyses. Efficacy analyses were based on the population of ITT patients who had at least one postbaseline evaluation for the specified efficacy measure (eg, HAM-D, CGI). Two types of analyses were performed for all efficacy variables: "last observation carried forward" (LOCF) and "observed cases" (OC). The LOCF analyses used the last valid assessment as an estimate for all subsequent missing values. The OC analysis did not replace missing data. The LOCF analyses were the primary analyses, and the OC analyses were the secondary analyses. Comparisons were based on a 2-sided test at an alpha level of 0.05, unless otherwise specified.

Differences between the treatment groups in the mean change from baseline in the continuous efficacy endpoints were assessed at each visit using a 2-way ANOVA with investigator, treatment, and treatment-by-investigator interaction as factors. The 90% confidence interval (CI) for the difference between the treatment groups was presented for the primary efficacy endpoint.

For the categorical efficacy endpoints, differences between the treatment groups were assessed at each visit using the Cochran-Mantel-Haenszel test, stratified by investigator.

Pharmacia — Company Confidential Page 6 of 342

PNU-155950E Study Report for M/2020/0032	a0098197 19 November 2001
Name of Company:	(For National Authority Use only)

Pharmacia	-	•
Name of Finished Product: (To be assigned)		
Name of Active Ingredient: Reboxetine mesylate		

SUMMARY OF RESULTS AND CONCLUSIONS: Disposition of Subjects and Baseline Characteristics:

The percentage of patients who completed the 8-week treatment period was similar among the treatment groups (65.1% [28/43]) in the reboxetine group and 69.0% [29/42] in the fluoxetine group). In the reboxetine group, the most common reason for discontinuation of study medication was withdrawal of consent, which led to discontinuation of treatment in 16.3% (7/43) of reboxetine-treated patients and 4.8% (2/42) of fluoxetine-treated patients. In the fluoxetine group, the most common reason for discontinuation of study medication was adverse events, which led to discontinuation of treatment in 14.3% (6/42) of fluoxetine-treated patients and 11.6% (5/43) of reboxetine-treated patients.

The patients in the study ranged in age from 19 to 64 years. All of the patients were Asian, and the majority (>60%) of the patients were female. No statistically significant differences were noted among the treatment groups in the severity of depression at baseline, as judged by the mean total scores for the HAM-D, the CGI Severity of Illness, or the SASS.

Efficacy Results:

The results of this study demonstrate that the reboxetine and fluoxetine groups were comparable on the primary endpoint, the mean change from baseline in the HAM-D total score at day 56 in the LOCF analysis. Strong evidence of antidepressant activity was observed in both treatment groups, as demonstrated by mean change from baseline values in the HAM-D total score of -14.05 in the reboxetine group and -14.78 in the fluoxetine group (p=0.971). The difference between the treatment groups in the mean change values (0.72; lower limit of 90% CI, -2.19) was not considered to be either clinically significant (because the difference was <2) or statistically significant (because the lower limit of the 90% CI was <0).

As summarized in the table, the results on the primary endpoint were supported by results on the secondary measures of antidepressant efficacy. No statistically significant differences were observed between the treatment groups in the HAM-D response or remission rates, the CGI Global Improvement response rate, or the mean change from baseline in the CGI Severity of Illness score at day 56 in the LOCF analysis. Thus, the results of both the primary and secondary measures of antidepressant efficacy were consistent in demonstrating the comparable efficacy of reboxetine and fluoxetine for the treatment of patients with depression.

Pharmacia — Company Confidential Page 7 of 342

PNU-155950E	a0098197
Study Report for M/2020/0032	19 November 2001
Name of Company:	(For National Authority Use only)

Pharmacia Name of Finished Product: (To be assigned)

Name of Active Ingredient: Reboxetine mesylate

Summary of Antidepressant Efficacy Measures at Day 56 (LOCF Analysis)			
Variable	Reboxetine N=43	Fluoxetine N=42	P Value
Primary Endpoint			
HAM-D total score, mean change from baseline	-14.05	-14.78	0.971
Secondary Endpoints			
% Responders or Remitters			
HAM-D Response	55.3	57.5	0.697
HAM-D Remission	36.8	40.0	0.593
CGI Global Improvement Response	71.1	70.0	0.905
Mean Change From Baseline			
CGI Severity of Illness	-2.0	-2.1	0.530
SASS total score	7.3	3.6	0.038*

 $p \le 0.05$ (reboxetine superior to fluoxetine)

Abbreviations: CGI = Clinical Global Impression, HAM-D = Hamilton Rating Scale for Depression, SASS = Social Adaptation Self-evaluation Scale

The results of the final secondary endpoint, the SASS total score, demonstrated that reboxetine is superior to fluoxetine for the improvement of social function. The mean change from baseline in the SASS total score was significantly greater in the reboxetine group (mean change of 7.3) than in the fluoxetine group (mean change of 3.6) at day 56 in the LOCF analysis (p=0.038).

The results of the OC analyses (secondary analyses) of the primary and secondary efficacy endpoints were similar to the results of the LOCF analyses.

Safety Results:

Treatment-emergent signs and symptoms (TESS) were reported in 86.0% (37/43) of the reboxetine-treated patients and 78.6% (33/42) of the fluoxetine-treated patients. In the reboxetine group, the most frequently reported TESS (reported in at least 10% of patients) were dry mouth, nausea, constipation, hypoesthesia, dizziness, shivering, fatigue, palpitations, urinary retention, and postural hypotension. In the fluoxetine group, the most frequently reported TESS (reported TESS (reported in at least 10% of patients) were dry mouth, nausea, constipation, hypoesthesia, dizziness, shivering, fatigue, palpitations, urinary retention, and postural hypotension. In the fluoxetine group, the most frequently reported TESS (reported in at least 10% of patients) were dry mouth, nausea, constipation, dizziness, headache, and fatigue.

Overall, the adverse-event profile that was observed for reboxetine in this study is consistent with the profile that was established in previous studies of reboxetine. Several adverse events, including hypoesthesia, shivering, palpitations, urinary retention, and postural hypotension, were reported at a higher frequency in this study than in the combined data from previous studies of reboxetine. However, the relevance of these differences is not clear, due to the small sample size of this study.

No deaths were reported during this study. Serious TESS were reported in an equal number of patients (3 patients) in both of the treatment groups.

Pharmacia — Company Confidential Page 8 of 342

PNU-155950E	a0098197
Study Report for M/2020/0032	19 November 2001

Name of Company: Pharmacia	(For National Authority Use only)
Name of Finished Product: (To be assigned)	
Name of Active Ingredient: Reboxetine mesylate	

The percentage of patients who discontinued treatment due to TESS was slightly lower in the reboxetine group (11.6%; 5/43) than in the fluoxetine group (14.3%; 6/42) group. No individual events led to discontinuation of treatment in more than 1 reboxetine-treated patient. Hypomania and suicide attempt each led to discontinuation of treatment in 2 fluoxetine-treated patients.

The majority of patients in each treatment group had postbaseline hematology and chemistry values that were within the predefined normal ranges. No evidence of a treatment-related effect was noted on any hematologic or chemistry assay.

No statistically significant changes from baseline values for sitting systolic or diastolic blood pressure were observed within either treatment group at any postbaseline evaluation.

Statistically significant changes from baseline values for pulse rate and ECG heart rate were observed in both treatment groups at each postbaseline evaluation. At the end of the study (day 56), the mean change from baseline pulse rate was +7.7 beats per minute in the reboxetine group and -6.4 beats per minute in the fluoxetine group, whereas the mean change from baseline ECG heart rate was +10.8 beats per minute in the reboxetine group and -6.1 beats per minute in the fluoxetine group. However, only 2 reboxetine-treated patients had postbaseline values for pulse rate that were above the predefined limit (\geq 120 beats/min), and no reboxetine-treated patients had postbaseline values for ECG heart rate that were above the predefined limit (\geq 120 beats/min).

CONCLUSION:

In conclusion, this phase III, multicenter, randomized, double-blind, active-controlled, parallel-group study demonstrated that the reboxetine and fluoxetine groups were comparable on the primary endpoint, the mean change from baseline in the HAM-D total score at day 56 in the ITT patient population. Overall, the adverse-event profile that was observed for reboxetine in this study is consistent with the profile that was established in previous studies of reboxetine. Several adverse events, including hypoesthesia, shivering, palpitations, urinary retention, and postural hypotension, were reported at a higher frequency in this study than in the combined data from previous studies of reboxetine. However, the relevance of these differences is not clear, due to the small sample size of this study. No new safety concerns associated with the use of reboxetine were identified.

Date of the Report: 19 November 2001

Pharmacia — Company Confidential Page 9 of 342

PNU-155950E	a0098197
Study Report for M/2020/0032	19 November 2001

TABLE OF CONTENTS

ABBREVIATIONS AND DEFINITION OF TERMS 16 ETHICS 16 2.1. Independent Ethics Committee 16 2.2. Ethical Conduct of the Study 17 2.3. Subject Information and Consent 17 3. INVESTIGATORS AND STUDY ADMINISTRATIVE STRUCTURE 17 4. INTRODUCTION 17
2.1. Independent Ethics Committee162.2. Ethical Conduct of the Study172.3. Subject Information and Consent173. INVESTIGATORS AND STUDY ADMINISTRATIVE STRUCTURE174. INTRODUCTION17
2.2. Ethical Conduct of the Study 17 2.3. Subject Information and Consent 17 3. INVESTIGATORS AND STUDY ADMINISTRATIVE STRUCTURE 17 4. INTRODUCTION 17
2.3. Subject Information and Consent
8. INVESTIGATORS AND STUDY ADMINISTRATIVE STRUCTURE
I. INTRODUCTION
5. OBJECTIVES AND ENDPOINTS
5.1. Objectives
5.1.1. Primary Objective
5.1.2. Secondary Objectives
5.2. Endpoints
5. METHODS
6.1. Overall Study Design and Plan
6.2. Discussion of Study Design
6.3. Selection of Study Population
6.3.1. Inclusion Criteria
6.3.2. Exclusion Criteria
6.4. Treatments
6.4.1. Treatments Administered
6.4.2. Identity of Investigational Product
6.4.3. Method of Assigning Subjects to a Treatment Group
6.4.4. Selection of Doses Used in the Study
6.4.5. Selection and Timing of Dose for Each Subject
6.4.6. Blinding
6.4.7. Prior and Concomitant Treatment
6.4.8. Treatment Compliance
6.4.9. Removal of Subjects From Treatment or Assessment

Pharmacia — Company Confidential Page 10 of 342

PNU-155950E 19 Study Report for M/2020/0032 19	a0098197 November 2001
6.5. Efficacy and Safety Variables	
6.5.1. Efficacy and Safety Measures Assessed	
6.5.2. Appropriateness of Measurements	
6.5.3. Efficacy Variables	
6.5.3.1. Primary Efficacy Variable	
6.5.3.2. Secondary Efficacy Variables	
6.5.4. Safety Variables	
6.5.4.1. Adverse Events	
6.5.4.2. Clinical Laboratory Evaluations	
6.5.4.3. Vital Signs, Physical Findings, and Other Observations Related to	Safety 33
6.6. Data Quality Assurance	
6.7. Statistical Methods Planned in the Protocol and Determination of Sample	e Size 34
6.7.1. Statistical and Analytical Plans	
6.7.1.1. Data Sets Analyzed	
6.7.1.2. Demographic and Baseline Characteristics	
6.7.1.3. Efficacy Measures	
6.7.1.4. Safety Data	
6.7.2. Determination of Sample Size	
6.8. Changes in the Conduct of the Study or Planned Analyses	
6.8.1. Protocol Amendments	
6.8.1.1. Amendment 1 (17 January 2000)	
6.8.1.2. Amendment 2 (30 June 2000)	
6.8.2. Changes in the Statistical Plan	
6.8.2.1. 90% Confidence Intervals	
6.8.2.2. Exclusion of Efficacy Data	
7. RESULTS	
7.1. Study Subject Information	
7.1.1. Disposition of Patients	
7.1.2. Protocol Deviations	
7.1.2.1. Deviations From Inclusion/Exclusion Criteria or Disallowed Conc Medications	

Pharmacia — Company Confidential Page 11 of 342

PNU-155950E Study Report for M/2020/0032 19 Nov	a0098197 vember 2001
7.1.2.2. Deviations From Planned Trial Conduct	41
7.1.3. Data Sets Analyzed	
7.1.4. Demographic and Other Baseline Characteristics	
7.1.4.1. Demographic Characteristics	
7.1.4.2. Psychiatric History	
7.1.5. Concomitant Medications and Other Therapies	
7.1.5.1. Prior to the Study	
7.1.5.2. During the Treatment Period	
7.2. Dosage Information	
7.2.1. Extent of Exposure	
7.3. Efficacy Results	
7.3.1. Data Sets Analyzed	
7.3.2. Primary Efficacy Variable	
7.3.2.1. Analysis of Data From All Visits	
7.3.2.2. Exclusion of Data From Telephone Interviews	
7.3.3. Secondary Efficacy Variables	
7.3.3.1. HAM-D Response Rate	
7.3.3.2. HAM-D Remission Rate	
7.3.3.3. CGI Severity of Illness	
7.3.3.4. CGI Global Improvement Response Rate	
7.3.3.5. Social Adaptation Self-evaluation Scale	
7.3.4. Efficacy Conclusions	
7.4. Safety Results	61
7.4.1. Treatment-Emergent Adverse Events	61
7.4.1.1. Brief Summary	61
7.4.1.2. All Treatment-Emergent Signs and Symptoms	
7.4.1.3. Drug-Related Treatment-Emergent Signs and Symptoms	
7.4.2. Deaths, Serious Adverse Events, and Other Significant Adverse Events	
7.4.2.1. Deaths	
7.4.2.2. Serious Treatment-Emergent Signs and Symptoms	
7.4.2.3. Discontinuations Due to Treatment-Emergent Signs and Symptoms	
Pharmacia — Company Confidential	

Page 12 of 342

PNU-155950E Study Report for M/2020/0032	a0098197 19 November 2001
7.4.2.4. Narrative Summaries	
7.4.3. Clinical Laboratory Evaluation	
7.4.3.1. Hematology	
7.4.3.2. Chemistries	
7.4.4. Vital Signs	77
7.4.4.1. Mean Change From Baseline	
7.4.4.2. Values Outside of Predefined Normal Ranges	
7.4.5. Electrocardiograms	
7.4.5.1. ECG Abnormalities	
7.4.5.2. Effects of Treatment on Heart Rate, PR, QRS, and QT Interv	als79
7.4.6. Exposure in Utero	
7.4.7. Safety Conclusions	
8. DISCUSSION AND OVERALL CONCLUSIONS	
9. ACKNOWLEDGMENTS	
10. REFERENCES LIST	
TABLES	
Table 1. Study Medications: Capsule Strength, Suppliers, and Lot Num	<u>bers</u> 24
Table 2. Schedule of Activities	
Table 3. Laboratory Assays	
Table 4. Patient Disposition	
Table 5. Protocol Deviations	
Table 6. Study Visits at Which Efficacy Scales Were Administered Via	Telephone
Interviews	
Table 7. Patient Demographics at Screen	
Table 8. Previous History of Depression	
Table 9. Previous Use of Psychotropic Medication Other Than Antidepr	<u>essants</u> 44
Table 10. Characteristics of the Present Depressive Episode	
Table 11. Severity of Depression at Baseline	
Table 12. Mean Daily Dose by Visit	
Table 13. Mean Change From Baseline in the HAM-D Total Score	
Table 14. HAM-D Response* Rate	

Pharmacia — Company Confidential Page 13 of 342

PNU-155950E Study Report for M/2020/0032	a0098197 19 November 2001
Table 15. HAM-D Remission* Rate	
Table 16. Mean Change From Baseline in the CGI Severity of Ill	Iness Score55
Table 17. CGI Global Improvement Response* Rate	
Table 18. Mean Change From Baseline in the SASS Total Score	
Table 19. Summary of Antidepressant Efficacy Measures at Day	56 (LOCF Analysis) 61
Table 20. Overall Summary of Treatment-Emergent Signs and S	
Table 21. Frequency of Treatment-Emergent Signs and Sympton Organ Class	· · ·
Table 22. TESS Reported in ≥5% of Patients in Either Treatment	<u>Group</u> 64
<u>Table 23. TESS Reported in ≥5% of Patients in Either Treatment</u> <u>Intensity</u>	* *
<u>Table 24. TESS Reported in ≥2 Male or Female Patients in Eithe</u> <u>Gender</u>	
Table 25. Drug-Related* TESS Reported in $\geq 5\%$ of Patients in E	ither Treatment Group 68
Table 26. Frequency of Serious TESS	
Table 27. Frequency of TESS That Led to Discontinuation of Tre	eatment 70
Table 28. Patients With Values Outside the Predefined Normal IFunction Tests at Day 56	
Table 29. Patients With at Least One Postbaseline Blood Pressur Outside of the Predefined Limits	
Table 30. Mean Change From Baseline ECG Intervals at Day 56	
Table 31. Patients With at Least One Postbaseline ECG Interval Limits	
Table 32. Summary of Antidepressant Efficacy Measures at Day	
FIGURES	
Figure 1. Study Design and Timeline	
TABLE SECTION	
APPENDICES	
Appendix 1. Study Information	
Appendix 1.1 Protocol and Amendments	

Pharmacia — Company Confidential Page 14 of 342

PNU-155950E Study Report for M/2020/0032	a0098197 19 November 2001
Appendix 1.2 Sample Case Report Forms	
Appendix 1.3 Sample Informed Consent	
Appendix 1.4 List of Investigators and Independent Ethics Committees	
Appendix 1.5 Curriculum Vitae for Investigators	
Appendix 1.6 List of Subjects Receiving Drug by Batch (not applicable)	
Appendix 1.7 Randomization Scheme	
Appendix 1.8 Audit Certificates (not applicable)	
Appendix 1.9 Documentation of Statistical Methods (not applicable)	
Appendix 1.10 Inter-Laboratory Standardization Methods (not applicable	e)
Appendix 1.11 List of Publications Based on the Study (not applicable)	
Appendix 1.12 Supporting Documentation Referenced in the Report (no	t applicable)
Appendix 1.13 Signature of Principle Investigator	
Appendix 2. Supportive Statistical Tables and Figures	
Appendix 3. Subject Data Listings	
Appendix 3.1 Discontinued Subjects	
Appendix 3.2 Protocol Deviations	
Appendix 3.3 Subjects Excluded from the Efficacy Analysis (not application)	able)
Appendix 3.4 Demographic Data	
Appendix 3.5 Compliance and/or Drug Concentration Data	
Appendix 3.6 Individual Efficacy Response Data (not applicable)	
Appendix 3.7 Adverse Event Listings	
Appendix 3.8 Listing of Individual Laboratory Measurements	
Appendix 4. Individual Subject Data Listings (provided upon request)	
Appendix 5. Case Report Forms (provided upon request)	

Pharmacia — Company Confidential Page 15 of 342

PNU-155950E	a0098197
Study Report for M/2020/0032	19 November 2001

1. ABBREVIATIONS AND DEFINITION OF TERMS

ALT	alanine aminotransferase
ANOVA	analysis of variance
AST	aspartate aminotransferase
CGI	Clinical Global Impression
CI	confidence interval
CRF	case report form
DSM-IV	Diagnostic and Statistical Manual of Mental Disorders - Fourth Edition
ECG	electrocardiogram
HAM-D	Hamilton Rating Scale for Depression
IEC	Independent Ethics Committee
ITT	intent to treat
LOCF	last observation carried forward
MedDRA	Medical Dictionary for Regulatory Activities
MDD	major depressive disorder
OC	observed cases
SASS	Social Adaptation Self-evaluation Scale
SSRI	selective serotonin reuptake inhibitors
TCA	tricyclic antidepressants
TESS	treatment-emergent signs and symptoms

2. ETHICS

2.1. Independent Ethics Committee

The protocol and all amendments for this study were reviewed by an Independent Ethics Committee (IEC) prior to the initiation of the study. Appendix 1.1 contains a copy of the protocol and its amendments, Appendix 1.2 contains copies of the unique pages of the case Pharmacia — Company Confidential

Page 16 of 342

PNU-155950E	a0098197
Study Report for M/2020/0032	19 November 2001

report forms (CRF), Appendix 1.3 contains a copy of a sample informed consent statement, and Appendix 1.4 lists the IECs that were consulted.

2.2. Ethical Conduct of the Study

Monitoring procedures performed prior to, during, and upon completion of this study have verified that this study was conducted in accordance with the ethical principles that have their origins in the Declaration of Helsinki. Appendix 3.2 lists the protocol deviations.

2.3. Subject Information and Consent

Prior to inclusion in the study, each patient was given adequate verbal and written information regarding the objectives and procedures of the study and the possible risks involved. All patients gave signed informed consent prior to inclusion in the study. Appendix 1.3 contains a copy of a sample informed consent form.

3. INVESTIGATORS AND STUDY ADMINISTRATIVE STRUCTURE

A total of 5 principal investigators participated in this trial at 5 centers in Taiwan. Appendix 1.4 lists the investigators and their affiliations. Appendix 1.5 provides a curriculum vitae for each investigator. Appendix 1.13 contains the signature of the coordinating investigator.

Laboratory tests were performed at a central laboratory (SmithKline Beecham Clinical Laboratories, Van Nuys, CA). Electrocardiogram (ECG) results were analyzed by Cardiac Alert (London, England).

4. INTRODUCTION

Major depression is a common disorder, with a lifetime prevalence of 2% to 12% in men and 5% to 26% in women [1]. A diagnosis of depression depends on the presence of significant depressed mood and associated affects, but loss of interest, loss of energy, and impaired social function are also inherent components of major depression [2].

Depression can be treated effectively by a range of antidepressant agents [3]. Approximately 50% to 70% of patients in clinical trials will respond to antidepressants but will fail to go into remission [4], whereas 25% to 35% will experience full remission after treatment with an effective antidepressant agent [4, 5]. Recent meta-analytic reviews have suggested that the selective serotonin reuptake inhibitors (SSRIs) offer equal efficacy to some of the older antidepressant agents (eg, the tricyclic antidepressants [TCAs]), with the advantage of greater tolerability, as assessed by attrition due to adverse events [6, 7, 8]. Other reviewers have suggested that SSRIs may be of more limited utility in more severely depressed patients and in patients with melancholic symptoms. For example, non-SSRI antidepressants, such as venlafaxine and clomipramine, have been found to be significantly more effective than fluoxetine for the treatment of patients with severe depression [9]. However, the studies that

PNU-155950E	a0098197
Study Report for M/2020/0032	19 November 2001

have found approximately equal outcomes on general measures of depression symptoms (eg, the Hamilton Rating Scale for Depression [HAM-D] total scores) do not provide any perspective on whether select agents offer superior treatment on a specific domain of depression symptoms.

Norepinephrine, one of the fundamental neurotransmitters of the brain, has been implicated in the neuronal systems that are important in vigilance, mood, and cognition. Modern neurochemical models of depression focus on the concept that norepinephrine is particularly important in the brain subsystems that underlie energy, interest, and motivation, whereas serotonergic systems have particular importance in modulating impulsivity. Both systems may overlap in modulating mood, sleep, anxiety, and appetite [10]. Current theories on depression have suggested that there are potential underlying genetic variations in the noradrenergic or serotoninergic systems. The suggestion has been made that roughly a quarter of depressions relate predominantly to noradrenergic problems, a quarter to serotoninergic problems, and that the remaining depressions relate to a mixture of these problems or other issues. This theory may explain why the SSRIs in general are associated with approximately one third full responses (normalization of HAM-D), one third partial responses (improvement but not normalization), and one third non-responses [4]. This conceptualization of depression implies the need for agents that are capable of specifically modifying brain norepinephrine systems. As such, this model is consistent with the original monoamine hypothesis of depression, which was first published by Schildkraut [11].

Reboxetine methanesulphonate (reboxetine mesylate, PNU-155950E, FCE 20124) is a highly selective norepinephrine reuptake inhibitor that has antidepressant activity. The affinity of reboxetine to bind to the norepinephrine reuptake transporter (1.1 nM) is similar to that of desipramine (1.2 nM) and higher than that of imipramine (24 nM), venlafaxine (1060 nM), fluoxetine (1015 nM), sertraline (420 nM), paroxetine (40 nM), or citalopram (4070 nM) [12, 13]. At clinically relevant doses, reboxetine does not block serotonin or dopamine reuptake, affect anticholinergic or antihistaminergic receptors, or affect cardiac conduction in the manner underlying the cardiotoxicity of the TCAs.

The currently available agents that affect the norepinephrine system have less receptor specificity than reboxetine and, more importantly, affect other pervasive neurotransmitter systems that produce histaminergic and anticholinergic symptoms, among others. The high level of norepinephrine-uptake selectivity and receptor specificity (ie, the relative lack of activity of reboxetine on other neurotransmitter systems) implies the potential utility of reboxetine as an antidepressant, particularly in depressions that are associated with underlying perturbations of the norepinephrine system and in patients who have symptoms that are associated with reduced energy, interest, and motivation.

The efficacy of reboxetine has been independently demonstrated in multiple short-term, randomized, double-blind, placebo-controlled studies (protocols 008 [14], 014 [15], 047 [16], and 091 [17]) and in a long-term, double-blind, placebo-controlled study (protocol 013 [18]).

Pharmacia — Company Confidential Page 18 of 342

PNU-155950E	a0098197
Study Report for M/2020/0032	19 November 2001

The analyses of the trial endpoints from the placebo-controlled studies indicates that a clinically relevant benefit is obtained from a short course of treatment with reboxetine.

In addition to improvements in depressive symptoms, treatment-associated improvements in social behavior (measured using the Social Adaptation Self-Evaluation Scale [SASS] [19]) were noted in one study [15]. In this study, reboxetine was statistically and clinically superior to both placebo and fluoxetine in improving social functioning. The improvement was evident in both the patients who were and were not in remission from their depressive symptoms and indicated a better quality of remission for social adaptation in the reboxetine-treated patients.

The most frequently reported adverse events associated with the administration of reboxetine, as determined from combined safety data from controlled and uncontrolled studies in which 2140 patients have been treated with reboxetine, are dry mouth, constipation, nausea, insomnia, dizziness, headache, and sweating. However, these events were usually mild to moderate in severity, and only a small proportion of patients discontinued treatment with reboxetine for these reasons.

This study (protocol M/2020/0032) was conducted to test the hypothesis that reboxetine is effective for the treatment of depression in a Taiwanese population. In addition, this study was conducted to test the hypothesis that a noradrenergic-specific agent, such as reboxetine, is effective for improving the social functioning of patients with depression.

5. OBJECTIVES AND ENDPOINTS

5.1. Objectives

5.1.1. Primary Objective

The primary objective of this study was to compare the antidepressant efficacy of reboxetine (administered at a dose of 8 to 10 mg/day for 8 weeks) with that of fluoxetine (administered at a dose of 20 to 40 mg/day for 8 weeks), as measured by the change from baseline in the 21-Item HAM-D total score at the last assessment in patients suffering from major depressive disorder (MDD).

5.1.2. Secondary Objectives

The secondary efficacy objective of this study was to further compare the efficacy of reboxetine (administered at a dose of 8 to 10 mg/day for 8 weeks) with that of fluoxetine (administered at a dose of 20 to 40 mg/day for 8 weeks), as measured by the change from baseline in the SASS total score and in the Clinical Global Impression (CGI) score at the last assessment in patients suffering from MDD.

The safety objective of this study was to compare the tolerability (based on adverse events, vital signs, safety laboratory tests, and ECGs) of reboxetine, administered at a dose of 8 to

Pharmacia — Company Confidential Page 19 of 342

PNU-155950E	a0098197
Study Report for M/2020/0032	19 November 2001

10 mg/day for 8 weeks, with that of fluoxetine, administered at a dose of 20 to 40 mg/day for 8 weeks, in patients suffering from MDD.

5.2. Endpoints

The primary endpoint was the change from baseline in the HAM-D total score at the last assessment.

The secondary efficacy endpoints included both continuous measures of efficacy, such as the mean change from baseline in the CGI Severity of Illness score and in the SASS total score, and categorical measures of efficacy, including the HAM-D response rate, the HAM-D remission rate, the CGI Global Improvement score, and the CGI Global Improvement response rate.

The secondary safety endpoints were adverse events, vital signs, safety laboratory tests, and ECGs. Adverse events and vital signs were assessed at each postbaseline visit. Safety laboratory tests and ECGs were obtained at screen, week 4, and week 8.

6. METHODS

6.1. Overall Study Design and Plan


This phase III, multicenter, randomized, double-blind, active-controlled, parallel-group study was conducted in 85 patients aged 18 to 65 years who suffered from MDD without psychotic features, as diagnosed using criteria defined by the Diagnostic and Statistical Manual of Mental Disorders—Fourth Edition (DSM-IV) [2].

The patients were selected from a population of patients who were hospitalized or were receiving care at outpatient or day-hospital clinics. Patients who had a score of \geq 22 on the 21-Item HAM-D at the screening visit and who met the other eligibility criteria were randomized to receive 8 weeks of treatment with reboxetine (8 mg/day, days 1-28; 8-10 mg/day, days 29-56) or fluoxetine (20 mg/day, days 1-28; 20-40 mg/day, days 29-56). The optional dose increase to 10 mg/day of reboxetine or 40 mg/day of fluoxetine was allowed after 4 weeks of therapy in those patients whom the investigator believed would benefit in terms of response and would adequately tolerate the increased dose. Study visits were conducted weekly during the first 4 weeks of treatment and every 2 weeks during the last 4 weeks of treatment. Efficacy measures and certain safety measures (adverse events and vital signs) were assessed at each visit (days 0, 7, 14, 21, 28, 42, and 56); laboratory tests and ECGs were measured at screen, day 28, and day 56.

The study design is presented in Figure 1.

Pharmacia — Company Confidential Page 20 of 342





* The washout period varied according to the class of drugs with which the patient was being treated at the time of enrollment (eg, 4 days for tricyclic antidepressants, 14 days for monoamine oxidase inhibitors and selective serotonin reuptake inhibitors other than fluoxetine, and 28 days for fluoxetine). Patients who were not being treated with antidepressant medication at the time of study enrollment could be randomized as soon as their laboratory test results were available and their eligibility was confirmed.

6.2. Discussion of Study Design

The double-blind, randomized, parallel-group design used in this study is generally recognized as one that provides an unbiased assessment of the efficacy and safety of an experimental drug. The washout period prior to administration of study medication varied according to the class of drugs with which the patient was being treated at the time of enrollment. The lengths of the washout periods were designed, based on the pharmacokinetics of each class of drugs, to allow sufficient time for elimination of the drug. This washout procedure has been used successfully in previous clinical studies with reboxetine.

6.3. Selection of Study Population

6.3.1. Inclusion Criteria

To be included in the study, patients must have met all of the following criteria:

- Diagnosis of MDD without psychotic features, as defined by DSM-IV.
- Male or female, of any race, between the ages of 18 and 65 years (inclusive).
- Total score of \geq 22 on the 21-Item HAM-D at screen and at baseline.
- General good health, as confirmed by routine clinical laboratory safety findings.

PNU-155950E	a0098197
Study Report for M/2020/0032	19 November 2001

• Voluntary consent to participate in the study, documented in a written Patient Informed Consent Form that was signed prior to the start of any study procedures at the screening visit.

6.3.2. Exclusion Criteria

Patients were excluded from the study for any of the following reasons:

- DSM-IV diagnosis of the following concomitant psychiatric disorders: MDD with psychotic features, cyclothymic disorder, bipolar I or bipolar II disorders, substance-related disorders, schizophrenia, or other psychotic disorders.
- Resistance to antidepressive treatment, defined as a lack of response to at least 2 previous courses of antidepressant medications administered at full doses for more than 1 month or prior failure to respond to treatment with reboxetine or fluoxetine.
- History of MDD associated with endocrine disorders: hypo- or hyper-thyroidism tested by thyroid-stimulating hormone and thyroxine, adrenal insufficiency, or Cushing's syndrome.
- Positive pregnancy test for females of childbearing potential.
- Refusal by female patients of childbearing age to use an effective contraceptive method during the study.
- Breast-feeding by female patients.
- Participation in any clinical study with an investigational compound in the 1 month preceding the study.
- History or presence of gastrointestinal, liver, or kidney disease or other conditions known to interfere with the absorption, distribution, metabolism, and excretion of drugs.
- History of seizures or brain injury; current evidence of clinically important hematopoietic, respiratory, or cardiovascular diseases; current evidence of urinary retention or glaucoma.
- Clinically important illness in the 4 weeks preceding the study that might have interfered with the conduct of the trial.
- Clinically relevant abnormal findings in the physical examination, laboratory tests, or ECG at admission.
- Treatment with electroconvulsive therapy in the 6 months preceding the study.
- Major risk of suicide as assessed by the investigator, a score of ≥3 on Item 3 of the HAM-D at screen or baseline, or a history of suicide attempt during the current depressive episode.
- History of hypersensitivity to reboxetine or fluoxetine.
- Use of medications that are potent inhibitors of the drug-metabolizing enzymes cytochrome p450-3A4 or cytochrome p450-2D6. These medications include azole

Pharmacia — Company Confidential Page 22 of 342

PNU-155950E	a0098197
Study Report for M/2020/0032	19 November 2001

antifungal agents, macrolide antibiotics (such as erythromycin), or fluvoxamine. Use of hormonal contraceptive medications was allowed during the study.

6.4. Treatments

6.4.1. Treatments Administered

During the washout period, 1 placebo tablet was administered orally, once daily (in the morning). The study medications that were administered during the treatment period (reboxetine, fluoxetine, and placebo) were provided as identically appearing capsules. Study medications were administered orally, twice daily.

During weeks 1 through 4 (days 1-28), reboxetine was administered in twice-daily doses of 4 mg, for a total daily dose of 8 mg of reboxetine. After 4 weeks of treatment, the reboxetine dose was increased to 10 mg/day in patients whom the investigator believed would benefit in terms of response and would adequately tolerate the increased dose. The increase to 10 mg/day was achieved by adding a placebo capsule to the morning dose (to maintain the study blind) and a 2-mg capsule to the evening dose.

During weeks 1 through 4 (days 1-28), fluoxetine was administered as a morning dose of 20 mg of fluoxetine and a evening placebo capsule (to maintain the study blind). After 4 weeks of treatment, the fluoxetine dose was increased to 40 mg/day in patients whom the investigator believed would benefit in terms of response and would adequately tolerate the increased dose. The increase to 40 mg/day was achieved by adding a 20-mg capsule to the morning dose and an additional placebo capsule to the evening dose (to maintain the study blind).

6.4.2. Identity of Investigational Product

Trial medication for the randomized treatment consisted of identically appearing capsules that contained reboxetine or fluoxetine. Placebo capsules (lactose-filled gelatin capsules) were provided to maintain the blinding of the study medications. The reboxetine and placebo supplies were manufactured and supplied by Pharmacia & Upjohn (Pharmacia). The fluoxetine (ProzacTM, Eli Lilly and Company, Indianapolis, IN) comparator was commercially available and was inserted into gelatin capsules by Pharmacia. Information about the study medications is summarized in Table 1.

PNU-155950E	a0098197
Study Report for M/2020/0032	19 November 2001

Study Medication	Capsule Strength	Suppliers	Lot Numbers
Reboxetine	4 mg (one 4-mg tablet)	Pharmacia	00427.05
Reboxetine	2 mg (1/2 of one 4-mg tablet)	Pharmacia	00427.06
Fluoxetine	20 mg (one 20-mg tablet)	Eli Lilly (repackaged by Pharmacia)*	00427.04
Placebo capsules†		Pharmacia	00427.03
Placebo tablets (washout period)		Pharmacia	H06A02

Table 1. Study Medications: Capsule Strength, Suppliers, and Lot Numbers

Prozac capsules, supplied by Eli Lilly and Company were inserted into gelatin capsules by Pharmacia
 Placebo capsules were used to maintain the blinding of the study medication.

The study medications were provided in bottles that were labeled with the protocol number, the patient number, and a label indicating whether the dose was to be administered in the morning or evening. Each patient received 2 bottles of study medication for each week during weeks 1 through 4; 1 bottle (labeled AM) contained capsules for the morning dose, and 1 bottle (labeled PM) contained capsules for the evening dose. Two extra capsules (for a total of 9 capsules) were included in each bottle to allow for unexpected delays in the scheduling of appointments.

Patients who received the optional dose increase to 10 mg/day of reboxetine or 40 mg/day of fluoxetine received 2 additional bottles of study medication for each week during weeks 5 through 8; 1 bottle (labeled AM-2) contained capsules for the additional morning dose, and 1 bottle (labeled PM-2) contained capsules for the additional evening dose.

Medications were dispensed to patients at each visit during the treatment period (baseline, weeks 1-4, and week 6). At the same visit, the patients returned the bottles that had been dispensed at the previous visit. All unused medications and empty bottles were returned to Pharmacia.

Drug supplies were stored at room temperature. All drug supplies were handled under the direct responsibility of the investigator. The study field monitor assessed the drug storage conditions during site visits.

6.4.3. Method of Assigning Subjects to a Treatment Group

Pharmacia prepared a randomization list for assignment of the patients to 1 of the 2 treatment groups. Study medication for each treatment group was prepared on this basis by Pharmacia and was labeled with the corresponding patient number. At the baseline visit, the investigator assigned each patient to a treatment group based on the patient's temporal entry into the study (ie, by assigning the lowest patient number available). A list of patient numbers and medication assignments was provided only after the data for the study had been analyzed.

Appendix 1.7 contains a copy of the randomization scheme and code.

Pharmacia — Company Confidential Page 24 of 342

PNU-155950E	a0098197
Study Report for M/2020/0032	19 November 2001

6.4.4. Selection of Doses Used in the Study

The 8- to 10-mg/day doses of reboxetine that were administered in this study were chosen based on the results of previously conducted phase II and phase III studies in which these doses were shown to provide maximal response rates with the most acceptable adverse-event profile. The doses of fluoxetine that were administered in this study (20 mg/day, with an optional increase to 40 mg/day) are the recommended doses for the treatment of depression [20].

6.4.5. Selection and Timing of Dose for Each Subject

During the first 4 weeks of the study, patients in both of the treatment groups took one capsule in the morning and one capsule in the late afternoon at an approximately fixed time (eg, between 8 and 9 AM and between 5 and 6 PM), for a total daily dose of 8 mg of reboxetine or 20 mg of fluoxetine.

An optional dose increase (to 10 mg/day of reboxetine or 40 mg/day of fluoxetine) was permitted for weeks 5 through 8 if the investigator believed that the patient would benefit in terms of response and would adequately tolerate the increased dose (ie, in patients who had shown little or no improvement in the objective measures of depressive symptoms but who had no significant difficulty in tolerating the initial doses of study medication). A patient whose dose was escalated at the 4-week evaluation (day 28) continued with the higher dose until treatment was completed (day 56), unless the patient was unable to tolerate the increased dose, in which case she/he could resume the regimen that was used during weeks 1 through 4 of the study.

6.4.6. Blinding

Patients were randomized to a treatment in a double-blind fashion in order to minimize potential bias in the evaluation of clinical response and safety. The randomized medication consisted of identically appearing capsules containing reboxetine, fluoxetine, or placebo. The capsules were provided in bottles that were labeled with the protocol number, the patient number, and a label indicating whether the dose was to be administered in the morning or evening.

Investigators were given sealed drug-disclosure sheets that contained information about each patient's treatment. These sheets were opened only in case of emergency, when knowledge of the treatment was necessary for proper management of the patient. If the treatment code was opened, this was recorded on the serious adverse event report form, which was signed by the investigator. The investigator immediately (within 24 hours) informed the study monitor and reported a full description of the reason for opening the code on the Adverse Event Form of the CRF. When the treatment code was opened, the patient was withdrawn from the study.

The sealed disclosure sheets were returned to Pharmacia at the end of the study.

Pharmacia — Company Confidential Page 25 of 342

PNU-155950E	a0098197
Study Report for M/2020/0032	19 November 2001

6.4.7. Prior and Concomitant Treatment

No concomitant psychotropic medications other than temazepam, lorazepam, flurazepam, estazolam, and oxazepam, which could be administered as sleep inducers on an as-needed basis, were allowed during the study. The administration of other psychotropic drugs was considered to be a protocol violation. Use of St. John's Wort was not allowed during the study.

Other therapy that was considered to be necessary for the patient's welfare was permitted at the investigator's discretion. All such therapy was recorded on the Concomitant Medication CRF.

No other investigational drug was allowed to be taken concomitantly with the study medication, and patients were not allowed to participate concurrently in any other clinical study. Over-the-counter medications were allowed as needed for symptomatic treatment; these were recorded along with other medications on the Concomitant Medication CRF.

6.4.8. Treatment Compliance

The investigator maintained a record of the study medications that were received from the sponsor, those that were dispensed, and those that were returned. Discrepancies between dispensed and returned study medications were recorded.

Treatment compliance was monitored by the investigators and was recorded on the appropriate CRF (eg, Medication Record CRF, Concomitant Medication CRF) at each visit. Acceptable treatment compliance was defined as an overall drug intake of at least 80% of the prescribed amount.

6.4.9. Removal of Subjects From Treatment or Assessment

Patients were withdrawn from the study medication if the investigator judged it to be medically necessary or if it was the wish of the patient. The reasons for the withdrawal of a patient from study medication were noted. Regardless of the reason for withdrawal, the patient was examined as soon as possible. Relevant samples (eg, laboratory tests, ECGs, and any diagnostic procedures that were considered necessary to define the event that led to patient withdrawal) were obtained and relevant assessments were completed according to the schedule of final assessments. The CRFs were completed and forwarded to Pharmacia.

6.5. Efficacy and Safety Variables

6.5.1. Efficacy and Safety Measures Assessed

The primary efficacy endpoint was the change from baseline in the total score of the 21-Item HAM-D at the last assessment. The secondary efficacy endpoints included both continuous measures of efficacy, such as the mean change from baseline in the CGI Severity of Illness

Pharmacia — Company Confidential Page 26 of 342

PNU-155950E	a0098197
Study Report for M/2020/0032	19 November 2001

score and in the SASS total score, and categorical measures of efficacy, including the HAM-D response rate, the HAM-D remission rate, the CGI Global Improvement score, and the CGI Global Improvement response rate.

Efficacy measures were assessed at each study visit (screen [HAM-D only] and days 0, 7, 14, 21, 28, 42, and 56).

The safety of the study medication was evaluated using the following safety measures:

- Standard medical history, obtained at screen.
- Standard clinical and physical examination, obtained at screen.
- Blood pressure and pulse, measured in the sitting position at each visit.
- Adverse events, recorded at baseline and at each subsequent visit.
- ECG, obtained at screen, day 28, and day 56 (end of treatment). The ECG results were analyzed by Cardiac Alert (London, England). Abnormal ECG patterns were assessed and the heart rate, PR, QRS, and QT intervals were measured.
- Laboratory assays: hematology and serum chemistries were performed at screen and on days 28 and 56, serum pregnancy tests (for females of childbearing potential) and a urine drug test were performed at screen and on day 56, and thyroid-function tests were performed at screen. Laboratory tests were performed at a central laboratory (SmithKline Beecham Clinical Laboratories, Van Nuys, CA).

The schedule of study activities is summarized in Table 2.

Pharmacia — Company Confidential Page 27 of 342

PNU-155950E Study Report for M/2020/0032 a0098197 19 November 2001

Table 2. Schedule of Activities								
		Study Day*						
Study Activity	Screen†	Baseline	7	14	21	28	42	56 ‡
Informed Consent	Х		-	Ĩ		Ĩ		Ĩ
Admission Checklist	Х							
Demographics	Х							
Diagnosis: DSM-IV	Х							
Medical history	Х							
Physical Exam	Х							
Medication History	Х							
Psychiatric History	Х							
ECG	Х					Х		Х
Laboratory	Х	§				Х		Х
Pregnancy test	Х							Х
Urine drug screen	Х							Х
Vital signs	Х	Х	Х	Х	Х	Х	Х	Х
21-Item HAM-D	Х	Х	Х	Х	Х	Х	Х	Х
CGI		Х	Х	Х	Х	Х	Х	Х
SASS		Х	Х	Х	Х	Х	Х	Х
Treatment Completion								Х
Study Medication			Х	Х	Х	Х	Х	Х
Record								
Concomitant Medication		Х	Х	Х	Х	Х	Х	Х
Adverse Events		Х	Х	Х	Х	Х	Х	Х
Post Study Follow-Up	As needed for adverse events or serious adverse events after study completion							

* Visits were targeted to occur within 1 day of the scheduled study day.

† The screening visit must have occurred within 2 weeks prior to baseline.

Day-56 measurements were completed at early termination if the patient did not complete the study.

§ If significant abnormalities were noted on a laboratory test at screen, then the test was to be repeated at the baseline visit.

Abbreviations: CGI = Clinical Global Impression, ECG = electrocardiogram, HAM-D = Hamilton Rating Scale for Depression, SASS = Social Adaptation Self-evaluation Scale

6.5.2. Appropriateness of Measurements

The efficacy and safety measures that were used in this study represent standardized and well-accepted measures of antidepressant efficacy and safety in clinical studies (see Sections 6.5.3 and 6.5.4 below).

6.5.3. Efficacy Variables

6.5.3.1. Primary Efficacy Variable

The primary endpoint was the change from baseline in the total score of the 21-Item HAM-D at the last assessment.

Pharmacia — Company Confidential Page 28 of 342

PNU-155950E	a0098197
Study Report for M/2020/0032	19 November 2001

The 21-Item HAM-D [21] is an observer-rated scale that is based on both a clinical interview and on observations of behavior made by an experienced clinician. This scale is well standardized and is intended to assess the state of the patient's condition at the time of the interview and over the preceding few days. The individual items on the HAM-D are graded according to severity on 0- to 2-point or 0- to 4-point scales. The HAM-D total score ranges from 0 to 62; scores of \geq 25 are associated with severe depression, scores between 18 and 24 are associated with moderate depression, and scores between 8 and 17 are associated with mild depression. Scores of \leq 10 are often used as the definition of disease remission. Response to study medication is defined as a decrease of \geq 50% from baseline in the HAM-D total score at the postbaseline assessment.

6.5.3.2. Secondary Efficacy Variables

The secondary efficacy endpoints were as follows:

- HAM-D response rate, defined as the percentage of patients who had a decrease of ≥50% from baseline in the 21-Item HAM-D total score
- HAM-D remission rate, defined as the percentage of patients who had a total score of ≤10 on the 21-Item HAM-D
- CGI Severity of Illness, mean change from baseline
- CGI Global Improvement, percentage of patients by Global Improvement score
- CGI Global Improvement response rate, defined as the percentage of patients who had a CGI Global Improvement score of ≤2 (corresponding to "very much improved")
- SASS, mean change from baseline in the total score

The CGI [22] is a clinician-rated scale that consists of the following 3 parts: Severity of Illness, Global Improvement, and Efficacy Index. Only the Severity of Illness and Global Improvement portions of the scale were used in this study. A mean decrease from baseline on the CGI Severity of Illness score represents patient improvement. The questions from the Global Improvement index refer to changes since the beginning of the study, as evaluated at each postbaseline visit, and are not asked at baseline. Lower scores on the CGI Global Improvement index indicate patient improvement; a responder is defined as a patient who has a score of ≤ 2 (corresponding to "very much improved" or "much improved").

The SASS [19] is a 21-question self-evaluation questionnaire that explores the domains of work and leisure, relationships, and patient perception of his/her ability to manage the environment. The scale was validated using data from 4000 individuals in a general population survey and data from 549 depressed patients who were enrolled in clinical studies that compared reboxetine with placebo and/or fluoxetine [19]. Each item of SASS is scored on a scale of 0 to 3, with a higher score indicating better social functioning. A total score in the range of 35 to 52 points is considered to be normal (ie, this range was observed in 80% of

Pharmacia — Company Confidential Page 29 of 342

PNU-155950E	a0098197
Study Report for M/2020/0032	19 November 2001

the general population) [19]. The SASS represents a useful tool for the evaluation of social functioning in depression because it is relatively simple to use and because it may help to differentiate the effects of different classes of antidepressants (eg, serotonergic agents regulating mood, noradrenergic agents sustaining drive) in a way that syndromic clinical rating scales are unable to do.

6.5.4. Safety Variables

6.5.4.1. Adverse Events

6.5.4.1.1. Definition of Adverse Events

For this study, an adverse event was defined as any untoward medical event that occurred during the protocol-specified adverse event reporting period (from baseline until the final clinic visit) regardless of whether it was considered to be related to study medication. In addition, any known untoward event that occurred subsequent to the adverse event reporting period and that the investigator assessed as possibly related to the investigational medication was also considered to be an adverse event.

Adverse events included all suspected adverse medication reactions; all reactions from medication abuse, withdrawal, sensitivity, or toxicity; apparently unrelated illnesses, including the worsening of a preexisting illness; any injury or accident; and any abnormality in physical examination or laboratory test results that required clinical intervention or further investigation (beyond ordering a repeat confirmatory test). If a medical condition was known to have caused the injury or accident (eg, a fall secondary to dizziness), then the medical condition (dizziness) and the accident (fall) were reported as 2 separate adverse events. The outcome of the accident (eg, hip fracture secondary to the fall) was recorded in the comments section of the CRF. Laboratory abnormalities that were associated with a clinical event (eg, elevated liver enzymes in a patient with jaundice) were described in the comments section of the CRF, rather than listed as a separate adverse event.

Diagnostic and therapeutic procedures, such as surgery, were not reported as adverse events. However, the medical condition for which the procedure was performed was reported if it met the definition of an adverse event (eg, an acute appendicitis that began during the adverse event reporting period would have been reported as an adverse event; the resulting appendectomy would have been noted in the comments section of the CRF).

Except for worsening of depressed mood (which would be reflected in a change in the HAM-D Item 1 score), an increase in the intensity of other symptoms of depression (eg, sleep difficulties, somatic symptoms, genital symptoms, weight change, anxiety, other psychiatric symptoms) was to be considered an adverse event if the intensity of the event increased during the treatment period.

Pharmacia — Company Confidential Page 30 of 342

PNU-155950E	a0098197
Study Report for M/2020/0032	19 November 2001

6.5.4.1.2. Eliciting Adverse Event Information

Investigators reported all directly observed adverse events and all adverse events that were spontaneously reported by the patients. In addition, each patient was questioned about adverse events at each clinic visit following initiation of treatment, as follows: "Since your last clinic visit," (or "Since you began taking the investigational medication,") "have you had any health problems?"

6.5.4.1.3. Adverse Events Reporting Period

The adverse event reporting period began with the administration of the first dose of study medication (at the baseline [day 0] visit) and ended at the final clinic visit (day 56). An adverse event that occurred during the protocol-specified adverse event reporting period was reported, regardless of whether it was considered to be related to the study medication. A disorder that was present before the adverse event reporting period started and that was noted on the pretreatment medical history/physical examination form was not reported as an adverse event reporting period. Any known untoward event that occurred subsequent to the adverse event reporting period and that the investigator assessed as possibly related to the study medication was considered to be an adverse event.

6.5.4.1.4. Assessment of Gravity and Intensity

Each adverse event was classified by the investigator as serious or nonserious. A serious adverse event was one that was fatal or life-threatening (ie, resulted in immediate risk of death), required or prolonged hospitalization, resulted in persistent or significant disability/incapacity, or was a congenital anomaly. Any other important adverse event that did not meet the preceding criteria was classified as serious if, based upon appropriate medical judgment, the event was considered to jeopardize the patient or if medical or surgical intervention was required to prevent the occurrence of one of the outcomes listed above. Serious adverse events also included any other adverse event that the investigator or company judged to be serious or that was defined as serious by the regulatory agency in the country in which the adverse event occurred.

Investigators characterized the intensity of adverse events as mild (did not interfere with patient's usual function), moderate (interfered to some extent with patient's usual function), or severe (interfered significantly with patient's usual function). The assessment of intensity was made independently of the assessment of gravity. It should be noted that severity is a measure of intensity, whereas seriousness is a measure of gravity. (A severe reaction is not necessarily a serious reaction. For example, a headache may be severe in intensity, but would not be classified as serious unless it met one of the criteria for serious events listed above.)

Pharmacia — Company Confidential Page 31 of 342

PNU-155950E	a0098197
Study Report for M/2020/0032	19 November 2001

6.5.4.1.5. Assessment of Drug-Relatedness

Investigators assessed the possible relationship between the adverse event and the study medication.

6.5.4.1.6. Follow-up of Unresolved Events

All adverse events were followed until they resolved or until the patient's participation in the study ended (ie, until a final report was completed for that patient). In addition, all serious adverse events and those nonserious events that were assessed by the investigator as possibly related to the study medication were followed after the patient's participation in the study was over, until the events resolved or until the investigator assessed them as "chronic" or "stable."

6.5.4.1.7. Exposure In Utero

If a patient became, or was found to be, pregnant while receiving or within 30 days of discontinuing study medication, then the investigator submitted an adverse event CRF that included the anticipated date of birth or pregnancy termination. The patient was followed by the investigator until the completion of the pregnancy. The following pregnancy outcomes were to be reported as serious adverse events: spontaneous abortion (including miscarriage and missed abortion), stillbirth, neonatal death within 1 month of birth, infant death that occurred after 1 month of birth and that the investigator assessed as possibly related to the in utero exposure, or congenital anomaly (including that in an aborted fetus). In the case of a live birth, the "normality" of the newborn was assessed at the time of birth (ie, there was no required minimum follow-up of a presumably normal infant). The "normality" of an aborted fetus was assessed by gross visual inspection unless pre-abortion laboratory findings were suggestive of a congenital anomaly.

6.5.4.2. Clinical Laboratory Evaluations

Hematology and serum chemistry assays were performed at screen and on days 28 and 56. Serum pregnancy tests (for females of childbearing potential) and a urine drug test were performed at screen and on day 56, and thyroid-function tests were performed at screen. The laboratory tests were performed at a central laboratory (SmithKline Beecham Clinical Laboratories, Van Nuys, CA).

The specific tests that were evaluated are summarized in Table 3.

PNU-155950E Study Report for M/2020/0032 a0098197 19 November 2001

Table 3. Laboratory Assays			
Category	Assay		
Hematology	Hematocrit		
	Hemoglobin		
	Leukocytes		
	Differential		
	Neutrophils		
	Lymphocytes		
	Monocytes		
	Eosinophils		
	Basophils		
	Platelet count		
	Erythrocytes		
Serum Chemistries	Electrolytes		
	Sodium		
	Potassium		
	Chloride		
	Carbon dioxide		
	Blood urea nitrogen		
	Creatinine		
	Glucose		
	Uric acid		
	Total bilirubin		
	Aspartate aminotransferase (AST)		
	Alanine aminotransferase (ALT)		
	Alkaline phosphatase		
	Thyroid stimulating hormone (TSH) and thyroxine		
	(T4) – screen only		
	Pregnancy test (for all females of childbearing		
	potential) – screen and day 56		
Urinalysis	Drug screen (screen and day 56)		

6.5.4.3. Vital Signs, Physical Findings, and Other Observations Related to Safety

Systolic and diastolic blood pressure and pulse were measured in the sitting position at each visit. Standard medical history and standard physical examinations were performed at screen.

ECGs were performed at screen and on days 28 and 56. The ECG results were analyzed by Cardiac Alert (London, England). Abnormal ECG patterns were assessed and the heart rate, PR, QRS, and QT intervals were measured.

6.6. Data Quality Assurance

The following procedures were implemented to ensure the quality of data that were collected:

- An investigator's meeting was held to familiarize the investigators with the protocol and with the assessment instruments.
- A reference manual was given to each investigator.

Pharmacia — Company Confidential Page 33 of 342

PNU-155950E	a0098197
Study Report for M/2020/0032	19 November 2001

- Data were collected on standard CRFs that were provided to each investigator by the sponsor.
- Investigators and institutions guaranteed access to source documents for quality assurance audits by Pharmacia personnel and the appropriate regulatory agencies.
- Monitoring visits were made periodically during the study to ensure that all aspects of the protocol were followed.
- Source documents were reviewed to verify their agreement with the data on the patient CRFs.
- All safety laboratory measurements were conducted by SmithKline Beecham Clinical Laboratories (Van Nuys, CA), a central laboratory that is certified by the Clinical Laboratory Improvement Act and the College of American Pathologists.
- Laboratory data were entered at SmithKline Beecham and were transmitted electronically to Pharmacia for analysis.
- ECGs were evaluated by Cardiac Alert (London, England); the ECG data were then transmitted electronically to Pharmacia for analysis.
- Data (ie, HAM-D scores and adverse events) in the clinical database were reviewed to verify their agreement with the data on the patient CRFs.
- Pharmacia's Standard Operating Procedures were followed in the conduct and analysis of the study.

Pharmacia is responsible for independent quality assurance audits of the clinical study processes at company sites worldwide. Audits of selected clinical investigator sites are also conducted to assess and help assure compliance with Good Clinical Practice and applicable regulatory requirements. Independent audits of this clinical study were not performed.

6.7. Statistical Methods Planned in the Protocol and Determination of Sample Size

6.7.1. Statistical and Analytical Plans

6.7.1.1. Data Sets Analyzed

The intent-to-treat (ITT) population includes all patients who were randomized into the trial and who received at least one dose of study medication. All analyses were based on the ITT population. Efficacy analyses were based on the population of ITT patients who had at least one postbaseline evaluation for the specified efficacy measure (eg, HAM-D, CGI).

Information regarding visit number or study day was based on the visit numbers that were preprinted on the CRFs. For purposes of data analysis, the day of first dose of study medication was considered to be study day 1.

Pharmacia — Company Confidential Page 34 of 342

PNU-155950E	a0098197
Study Report for M/2020/0032	19 November 2001

Two types of analyses were performed for all efficacy variables: "last observation carried forward" (LOCF) and "observed cases" (OC). The LOCF analyses used the last valid assessment as an estimate for all subsequent missing values. The OC analysis did not replace missing data. The LOCF analyses were the primary analyses, and the OC analyses were the secondary analyses. Comparisons were based on a 2-sided test at an alpha level of 0.05, unless otherwise specified.

6.7.1.2. Demographic and Baseline Characteristics

The demographic and baseline characteristics (eg, age, sex, race) of the patients in each treatment group were compiled. Categorical variables were summarized using frequency counts. The association between treatment groups and categorical variables was assessed using the chi-square test. Continuous variables were summarized using treatment group means, standard deviations, and ranges. The association between treatment groups and continuous variables was assessed using a 1-way analysis of variance (ANOVA) with treatment as a factor.

6.7.1.3. Efficacy Measures

6.7.1.3.1. Continuous Endpoints

Differences between the treatment groups in the mean change from baseline on the continuous efficacy endpoints were assessed at each visit using a 2-way ANOVA with investigator, treatment, and treatment-by-investigator interaction as factors. The treatment-by-investigator interaction was tested to evaluate the poolability of the data. If a statistically significant ($p \le 0.10$) interaction effect was observed, then the results from individual investigators were presented to identify the source of the interaction.

On the primary efficacy endpoint (the HAM-D total score), a difference of 2 points on the change from baseline is generally considered to be a clinically relevant difference between treatment groups. Therefore, the protocol specified that both the difference between the treatment groups and the 90% confidence interval (CI) for the difference would be presented. If a clinically relevant difference between treatment groups was observed, then the statistical significance of the difference was evaluated based on the 90% CI. A clinically relevant difference was considered to be statistically significant if the 90% CI did not include 0 (ie, the lower limit of the 90% CI was >0). Thus, reboxetine was considered to be inferior to fluoxetine on the primary endpoint if the conditions for both a clinically relevant difference (difference of 2 points on the change from baseline) and a statistically significant difference (lower limit of 90% CI >0) were met.

Mean values for the individual items of the HAM-D were displayed by treatment group and by visit to identify any items that may have exerted a major influence on the total score; this analysis was descriptive and did not include statistical hypothesis testing.

Pharmacia — Company Confidential Page 35 of 342

PNU-155950E	a0098197
Study Report for M/2020/0032	19 November 2001

6.7.1.3.2. Categorical Endpoints

For the categorical efficacy endpoints, differences between the treatment groups were assessed at each visit using the Cochran-Mantel-Haenszel test, stratified by investigator.

6.7.1.4. Safety Data

The original terms that were used by investigators to identify adverse events on the CRFs were translated according to the Medical Dictionary for Regulatory Activities (MedDRA) and were grouped according to the MedDRA system organ classes and preferred terms.

Each adverse event was counted once, according to the date of onset. If the adverse event began prior to the first dose of study medication and did not increase in severity after the first dose of study medication, then the adverse event was considered to be a pretreatment event and was not counted in the adverse event frequency tables. If the onset was prior to the first dose of study medication and the severity increased after baseline, then the event was considered to be an adverse event and was included in the adverse event frequency tables. This rule was consistent with the treatment-emergent signs and symptoms (TESS) convention for counting adverse events.

The incidence of TESS was summarized as follows: (1) by system organ class and preferred term; (2) by maximum severity; (3) by relationship to study medication; and (4) by gender. The relationship of an adverse event to study medication was based on the investigator's judgment. Summary tables were also presented for adverse events that resulted in termination of study medication, for serious adverse events, and for serious adverse events that resulted in termination of study medication. Corresponding patient data listings were prepared to support each of the above summaries.

For each vital sign, laboratory test, and ECG measure, the change from baseline at each postbaseline evaluation was analyzed using a paired *t* test. Differences between the treatment groups in the change from baseline at each postbaseline evaluation were analyzed using an ANOVA. The incidence of abnormal postbaseline vital signs, laboratory tests, and ECG results were summarized and corresponding patient data listings were prepared to support each of the summaries.

6.7.2. Determination of Sample Size

The sample size of 40 patients per treatment group was established after consultation with Taiwanese regulatory authorities.

The power calculation was based on the results of a previously conducted placebo- and fluoxetine-controlled study of reboxetine (protocol 014) in which the mean change from baseline in the HAM-D total score at week 8 was similar in the reboxetine (13.4 points) and fluoxetine (13.3 points) groups, with a standard deviation of approximately 9.0 points. A difference between 2 treatment groups of 2 points or less in the mean change from baseline in

Pharmacia — Company Confidential Page 36 of 342

PNU-155950E	a0098197
Study Report for M/2020/0032	19 November 2001

the HAM-D total score is generally considered to be clinically insignificant. With a sample size of 40 patients per treatment group, the power to detect a difference of more than 2 points in the mean change from baseline in the HAM-D total score is 0.25 with a 1-sided alpha equal to 0.05 and a common standard deviation of 9.0.

Power calculations were made with nQuery Advisor Release 3.0, Statistical Solutions Ltd., Cork, Ireland.

6.8. Changes in the Conduct of the Study or Planned Analyses

6.8.1. Protocol Amendments

Changes to protocol M/2020/0032 were detailed in 2 amendments, which were implemented before any patients were enrolled in the study. The protocol and protocol amendments are provided in Appendix 1.1. The amendments, along with the reasons for each, are briefly summarized below.

6.8.1.1. Amendment 1 (17 January 2000)

The protocol was amended to make the following changes or clarifications:

- The term "fixed-dose" was removed from the description of the study design, since dose-escalation was permitted in this study.
- The reference to a 40-mg fluoxetine capsule was removed from the description of the trial products, since only 20-mg fluoxetine capsules were used in this study.
- The description of the treatment schedule was changed to specify that all patients would receive placebo tablets during the washout period. (The original protocol indicated that the placebo washout tablets could be used at the investigator's request.)
- The description of the optional dose increase (to 10 mg/day of reboxetine or 40 mg/day of fluoxetine) was modified to clarify the description of the patients who would receive the dose-escalation. The original protocol stated that "These patients will generally be those who have had little or no improvement in their objective measures of depressive symptoms." With this amendment, the terms "little or no improvement" were defined as a change from baseline of ≤20% in the HAM-D total score or a score of ≥3 on the CGI Global Improvement scale. However, it should be noted that this definition was provided only as a guideline. The dose could be increased in any patient whom the investigator believed would benefit in terms of response and would adequately tolerate the increased dose.

6.8.1.2. Amendment 2 (30 June 2000)

The protocol was amended to make the following changes or clarifications:

Pharmacia — Company Confidential Page 37 of 342

PNU-155950E	a0098197
Study Report for M/2020/0032	19 November 2001

- The background information was updated to include data from 5 additional, short-term, placebo-controlled studies of reboxetine.
- The study design was modified to specify that the primary endpoint is the mean change from baseline in the 21-Item HAM-D total score, rather than the absolute change from baseline in the 21-Item HAM-D total score.
- The list of exclusion criteria was expanded to require that patients who had previously failed treatment with reboxetine or fluoxetine were to be excluded from the study.
- The planned analysis of ECG data was modified to specify that heart rate and PR, QRS, and QT intervals would be measured, but that the QTc interval would not be calculated.
- The statistical analysis plan was revised to clarify the power calculation and to eliminate the planned analysis of TESS by age (≤ 65 or >65 years), since only patients who are ≤ 65 years of age were enrolled in this study.

6.8.2. Changes in the Statistical Plan

6.8.2.1. 90% Confidence Intervals

As discussed in Section 6.7.1.3.1, the difference between the treatment groups on the primary endpoint was evaluated in terms of the clinical relevance and the statistical significance of the difference. If a clinically relevant difference between the treatment groups was observed (defined as a difference of 2 points on the change from baseline in the HAM-D total score), then the statistical significance of the difference was evaluated based on the 90% CI.

The protocol specified that the 90% CI for the difference between treatment groups would be presented for all efficacy variables (not just the primary endpoint). However, for the secondary efficacy endpoints, generally accepted definitions of clinically relevant differences were not available. Therefore, the differences between the treatment groups and the 90% CI for the differences were not presented for the secondary efficacy endpoints.

6.8.2.2. Exclusion of Efficacy Data

Although the rule was not specifically stated in the protocol, any efficacy measures that were completed at least 2 weeks after the patient's last dose of study medication (for patients who discontinued early from the study) were excluded from the efficacy analysis.

7. RESULTS

Key data tables are included in the text and are numbered sequentially (eg, Table 1, Table 2). More detailed, supportive tables are included in the end-of-text Tables and Figures section and are numbered separately with a "T" prefix (eg, Table T1, Table T2). References to these end-of-text tables are included in the text.

Pharmacia — Company Confidential Page 38 of 342

PNU-155950E	a0098197
Study Report for M/2020/0032	19 November 2001

7.1. Study Subject Information

7.1.1. Disposition of Patients

A total of 85 patients were enrolled in the study and were randomized to receive treatment with reboxetine (43 patients) or fluoxetine (42 patients). All of the randomized patients received at least 1 dose of study medication. Therefore, the ITT population includes 43 reboxetine-treated patients and 42 fluoxetine-treated patients.

The percentage of patients who completed the 8-week treatment period was similar among the treatment groups (65.1% reboxetine and 69.0% fluoxetine). The reasons for study discontinuation are summarized in Table 4.

	Re	Reboxetine		oxetine
	n	%*	n	%*
Number of patients				
Randomized	43	100.0	42	100.0
Intent to treat	43	100.0	42	100.0
Completed study	28	65.1	29	69.0
Discontinued study	15	34.9	13	31.0
Reason for discontinuation	on			
Adverse event	5	11.6	6	14.3
Consent withdrawn	7	16.3	2	4.8
Lost to follow-up	1	2.3	2	4.8
Protocol-specific	0	0	1	2.4
withdrawal criteria				
Lack of efficacy	2	4.7	1	2.4
Progression of disease	0	0	1	2.4

* Percentages are based on the number of patients who were randomized.

Source: Table T1

In the reboxetine group, the most common reason for discontinuation of study medication was withdrawal of consent, which led to discontinuation of treatment in 16.3% (7/43) of reboxetine-treated patients and 4.8% (2/42) of fluoxetine-treated patients. Of the 7 reboxetine-treated patients who withdrew consent, 5 patients (patient nos. 211, 227, 256, 258, and 274) were enrolled at Dr. Lu's site and 2 patients were enrolled at other sites (patient no. 230 at Dr. Lin's site and patient no. 265 at Dr. Lee's site). According to comments on the treatment-termination CRF, patient no. 211 refused to return for the next study visit (no reason given), patient no. 227 refused to return because she disagreed with the diagnosis of MDD, patient no. 258 refused to return because she thought that she was getting better, patient no. 230 did not take the study medications as scheduled, patient no. 274 discontinued from the study because she wanted to visit another doctor for the treatment of insomnia (although insomnia was not reported as an adverse event for this patient), and patient no. 256 discontinued from the study because she was concerned about dry mouth (dry mouth was reported as an adverse event). No comments were provided on the treatment-termination CRF for patient no. 265.

PNU-155950E	a0098197
Study Report for M/2020/0032	19 November 2001

In the fluoxetine group, the most common reason for discontinuation of study medication was adverse events, which led to discontinuation of treatment in 14.3% (6/42) of fluoxetine-treated patients and 11.6% (5/43) of reboxetine-treated patients. (Discontinuations due to adverse events are discussed in Section 7.4.2.3.)

Table T2 summarizes patient enrollment by investigator. The patients who prematurely discontinued from the study are listed in Appendix 3.1.

7.1.2. Protocol Deviations

7.1.2.1. Deviations From Inclusion/Exclusion Criteria or Disallowed Concomitant Medications

The occurrences of the following protocol deviations were summarized in each treatment group: (1) HAM-D total score of <22 at screen or baseline, (2) HAM-D Item 3 score of \geq 3 at screen or baseline, (3) positive serum pregnancy test at screen, (4) use of disallowed psychotropic medications, and (5) positive urine drug test at screen (Table 5).

Table 5. Protocol Deviations					
Reboxetine N=43		Fluoxetine N=42			
n	%	n	%		
1*	2.3	0	0		
3	7.0	9	21.4		
1	2.3	0	0		
20	46.5	21	50.0		
0	0	3	7.1		
	Rebo N 1* 3 1	Reboxetine N=43 n % 1* 2.3 3 7.0 1 2.3 20 46.5	Reboxetine N=43 Fluc N n % n 1* 2.3 0 3 7.0 9 1 2.3 0 20 46.5 21		

Table 5. Protocol Deviations

This patient (patient no. 238) had HAM-D total scores of 31 at the screening visit and 21 at the baseline visit.

† Based on information recorded on the concomitant medication case report form

The urine drug screen tested for the presence of the following: amphetamines, barbiturates, benzodiazepines, marijuana metabolites, cocaine metabolites, methadone, methaqualone, opiates, phencyclidine, and propoxyphene. However, because the use of certain benzodiazepines was allowed during the study (and the urine drug screen does not distinguish between allowed and disallowed benzodiazepines), positive results for benzodiazepines are not counted in this table.
 Source: Appendices 3.2 and 3.8.6

Although the protocol specified that female patients who had a positive serum pregnancy test at screen were to be excluded from the study, 1 patient (patient no. 298 in the reboxetine group) had a positive test at screen and at baseline. This patient had been pregnant and had undergone a dilatation and curettage procedure approximately 1 month before the screening visit. Before the patient was enrolled in the study, an ultrasound examination was performed, which confirmed that the pregnancy had been terminated. Therefore, the elevated HCG value was attributed to the previously terminated pregnancy, and the patient was enrolled in the study. At the end of the study (week 8), the pregnancy test result was negative for this patient.

Pharmacia — Company Confidential Page 40 of 342

PNU-155950E	a0098197
Study Report for M/2020/0032	19 November 2001

Although, the protocol specified that patients who had a HAM-D Item-3 score of \geq 3 at the screen or baseline visit were to be excluded from the study, 3 reboxetine-treated patients (patient nos. 272, 277, 288) and 9 fluoxetine-treated patients (patient nos. 219, 225, 226, 229, 257, 271, 279, 287, 289) who had HAM-D Item-3 scores of \geq 3 at the screen or baseline visits were enrolled in the study. All 12 patients were enrolled at a single study site (Dr. Lu). Comments on the CRF indicated that the investigator considered suicidal ideation to be characteristic of major depression and not a reason to exclude the patient from the study. None of the 12 patients who had HAM-D Item 3 scores of \geq 3 at the screen or baseline visits and were enrolled in the study attempted suicide during the study.

The protocol specified that no concomitant psychotropic medications other than temazepam, lorazepam, flurazepam, estazolam, and oxazepam, which could be administered as sleep inducers on an as-needed basis, were allowed during the study. However, concomitant use of disallowed psychotropic medications were reported in 46.5% (20/43) of reboxetine-treated patients and 50.0% (21/42) of fluoxetine-treated patients (based on information recorded on the concomitant medication CRF). Of the 20 reboxetine-treated patients and 21 fluoxetine-treated patients (8 reboxetine-treated patients and 13 fluoxetine-treated patients) were enrolled at the same study site (Dr. Lu). The concomitant psychotropic medications that were used were primarily short-acting benzodiazepines other than the benzodiazepines that were specifically allowed by the protocol (Table T10.2). In approximately half of the cases, the disallowed concomitant medications were the allowed benzodiazepines. No evidence of the concomitant use of antidepressant medications (other than the study medications) was observed during the study.

Other than benzodiazepines (which were discussed above based on information recorded on the concomitant medication CRF), the only drugs that were detected on the urine drug screen were marijuana metabolites, which were detected in 1 fluoxetine-treated patient (patient no. 271 at screen and day 28), and opiates, which were detected in 2 fluoxetine-treated patients (patient no. 269 at screen and patient no. 208 at day 56).

Patients who met the criteria for protocol deviations are listed with their adverse event profiles in Appendix 3.2. Concomitant medications that were taken during the study are listed in Table T10.2, and positive urine drug screen results are listed in Appendix 3.8.6.

7.1.2.2. Deviations From Planned Trial Conduct

The protocol specified that the efficacy scales, including the HAM-D, CGI, and SASS, were to be administered during the in-clinic study visits. However, at 3 of the 5 study sites, the efficacy scales were administered via telephone interviews when patients were unable to return to the clinic for a scheduled study visit. As summarized in Table 6, telephone interviews were conducted for 13 patients and accounted for a total of 18 study visits.

PNU-155950E Study Report for M/2020/0032 a0098197 19 November 2001

Were Administered Via Telephone Interviews				
Investigator	Patient No.	Treatment Group	Study Visit (Day)*	
Chiu	295	FLX	14 and 42	
Lee	247	RBX	42	
	264	FLX	42	
Lu	210	FLX	21	
	211	RBX	7 and 56	
	212	FLX	7	
	215	FLX	14 and 21	
	216	RBX	7	
	222	RBX	28	
	224	RBX	21	
	275	FLX	56	
	276	RBX	42 and 56	
	277	RBX	42 and 56	
* Study visi			e administered via	

Table 6. Study Visits at Which Efficacy Scales

* Study visit at which the efficacy scales were administered via telephone interviews.

Abbreviations: FLX = fluoxetine, RBX = reboxetine

To determine whether the use of telephone interviews affected the efficacy results, 2 separate analyses of the data from the HAM-D, CGI, and SASS scales were conducted. The first analysis included data for all visits (those conducted in the clinic or via telephone interviews), whereas the second analysis excluded the data that were collected during telephone interviews. The results of both analyses are included in the Tables section of this report.

7.1.3. Data Sets Analyzed

The ITT population includes all patients who were randomized into the trial and who received at least 1 dose of study medication. All of the 85 randomized patients received at least 1 dose of study medication. Therefore, the ITT population includes 43 reboxetine-treated patients and 42 fluoxetine-treated patients (Table T1).

All analyses were based on the ITT population. Efficacy analyses were based on the population of ITT patients who had at least one postbaseline evaluation for the specified efficacy measure (eg, HAM-D, CGI).

7.1.4. Demographic and Other Baseline Characteristics

7.1.4.1. Demographic Characteristics

No statistically significant differences were noted among the treatment groups in the age, sex, or race of patients at screen. The patients in the study ranged in age from 19 to 64 years. All of the patients were Asian, and the majority (>60%) of the patients were female. Selected demographic characteristics are compared by treatment group in Table 7.

Pharmacia — Company Confidential Page 42 of 342

PNU-155950E Study Report for M/2020/0032 a0098197 19 November 2001

Table 7. Patient Demographics at Screen				
		Reboxetine	Fluoxetine	
Vari	able	N=43	N=42	P Value*
Age, years	$\text{Mean}\pm\text{SD}$	40.65 ± 14.57	35.98 ± 12.70	0.119
	Range	19.0 - 64.2	19.6 - 62.0	
Sex: n (%)	Male	16 (37.2%)	16 (38.1%)	0.933
	Female	27 (62.8%)	26 (61.9%)	
Race: n(%)	Asian or	43 (100%)	42 (100%)	
	Pacific			
	Islander			

P values for continuous variables are based on a 1-way ANOVA with treatment as the main effect; p values for categorical variables are based on a chi-square test.

Source: Table T3

No statistically significant differences were noted between the treatment groups in the other continuous (eg, height or weight) or categorical (eg, patient's educational background, occupation, living situation, or current employment status) demographic characteristics that were assessed at screen. Likewise, no statistically significant differences were noted between the treatment groups in the mean systolic or diastolic blood pressure or pulse rate values at baseline (Table T3).

No statistically significant differences were noted between the treatment groups in the proportion of patients who had normal or abnormal physical examinations (Table T6). Although statistical testing was not performed, the findings for medical histories were generally similar between the 2 treatment groups (Table T7).

Appendix 3.4 contains a listing of demographic data by subject.

7.1.4.2. Psychiatric History

7.1.4.2.1. Previous History of Depression

No statistically significant differences were noted between the treatment groups in the mean age of patients at the onset of their first depressive episode, in the mean number of previous depressive episodes, or in the mean duration of the previous episode. Likewise, no statistically significant differences were noted between the treatment groups in the number of patients who were previously hospitalized for depression or in the mean age of patients at the time of their first hospitalization. Although a statistically significant difference was noted between the treatment groups in the mean number of previous hospitalizations for depression, this difference is considered to be of little relevance because of the small number of patients on which it is based (4 patients in the reboxetine group and 1 patient in the fluoxetine group) (Table 8).

Pharmacia — Company Confidential Page 43 of 342

PNU-155950E Study Report for M/2020/0032 a0098197 19 November 2001

Table 8. Previous History of Depression						
Variable	Reboxetine N=43	Fluoxetine N=42	P Value†			
Age (years) at onset of major de	epression					
n	42	42				
Mean \pm SD	37.7 ± 15.0	32.4 ± 12.2	0.077			
Range	17 - 63	15 - 56				
Number of previous episodes						
n	38	41				
Mean \pm SD	0.9 ± 1.8	1.2 ± 2.6	0.549			
Range	0 - 10	0 - 15				
Approximate duration of last ep	Approximate duration of last episode (weeks)					
n	17	22				
Mean \pm SD	29.2 ± 47.5	$\textbf{23.8} \pm \textbf{28.6}$	0.663			
Range	0.0 - 182.0	1.0 - 104.0				
Previous hospitalization for dep	ression					
No. (%) of patients who were ever hospitalized	4 (9.3%)	1 (2.4%)	0.175			
No. of hospitalizations						
n	4	1				
Mean \pm SD	1.8 ± 1.0	$8.0 \pm NA$	0.010*			
Range	1 - 3	8 - 8				
Age at first hospitalization						
n	3	1				
Mean \pm SD	42.0 ± 19.7	$47.0 \pm NA$	0.846			
Range	21 - 60	47 - 47				

* p≤0.05
 † P values for continuous variables are based on a 1-way ANOVA with treatment as the main effect; p values for categorical variables are based on a chi-square test. Source: Table T4

7.1.4.2.2. Previous Use of Psychotropic Medication Other Than Antidepressants

No statistically significant differences were noted among treatment groups in the previous use of psychotropic medications other than antidepressants. The most commonly used psychotropic medications other than antidepressants were benzodiazepines, which were previously used by 46.5% (20/43) of reboxetine-treated patients and 47.6% (20/42) of fluoxetine-treated patients (Table 9).

Table 9. Previous Use of Psychotropic Medication Other Than Antidepressants

Variable	Rebox N=			xetine =42	P Value*
	n	%	n	%	
Any psychotropic medication other than antidepressants	19	44.2	22	52.4	0.385
Benzodiazepines	20	46.5	20	47.6	0.573
Anti-psychotics	0	0	1	2.4	
Other	2	4.7	3	7.1	

* P values are based on a chi-square test. Source: Table T4

> Pharmacia — Company Confidential Page 44 of 342

PNU-155950E	a0098197
Study Report for M/2020/0032	19 November 2001

7.1.4.2.3. Characteristics of the Present Depressive Episode

No statistically significant differences were noted among the treatment groups at screen in the other characteristics of the present depressive episode (Table 10). The majority (>60%) of patients in each treatment group were receiving no treatment immediately prior to screen. The mean duration of the present depressive episode was 24 weeks in the reboxetine group and 23 weeks in the fluoxetine group. The present episode was diagnosed as a recurrent episode in approximately half of the patients in each treatment group (48.8% in the reboxetine group).

Table IV. Characteristic	s of the fresch	Depressive E	pisoue
Variable	Reboxetine N=43	Fluoxetine N=42	P Value*
			P value
No. (%)† of patients by treatment sta	tus immediately pric	or to screen	
No treatment	27 (62.8)	26 (61.9)	0.720
Outpatient treatment only	14 (32.6)	14 (33.3)	
Partial hospitalization	0	1 (2.4)	
(day treatment)			
Inpatient treatment	2 (4.7)	1 (2.4)	
Approximate duration of present epi	sode		
Mean ±SD (weeks)	23.86 (33.97)	22.87 (34.45)	0.8936
Range (weeks)	0.7 - 104.0	0.4 - 208.0	
No. (%)† of patients whose present e	pisode was diagnos	sed as:	
Single episode	22 (51.2)	19 (45.2)	0.5847
Recurrent episode	21 (48.8)	23 (54.8)	
No. (%)† of patients whose present e	episode was best ch	aracterized as:	
Exacerbation of chronic condition	9 (20.9)	2 (4.8)	0.0908
Recurrence of similar previous	15 (34.9)	21 (50.0)	
conditions			
Significantly different from any	0	1 (2.4)	
previous conditions			
First occurrence, no previous	19 (44.2)	18 (42.9)	
psychiatric diagnosis			

 Table 10.
 Characteristics of the Present Depressive Episode

* P values for continuous variables are based on a 1-way ANOVA with treatment as the main effect; p values for categorical variables are based on a chi-square test. Source: Tables T4, T5

7.1.4.2.4. Severity of Depression at Baseline

No statistically significant differences were noted among the treatment groups in the severity of depression at baseline, as judged by the mean total scores for the HAM-D, the CGI Severity of Illness, or the SASS (Table 11). A statistically significant difference was noted among the treatment groups in the mean HAM-D Item 1 score at baseline, which was lower in the reboxetine group (2.5) than in the fluoxetine group (2.8).

PNU-155950E Study Report for M/2020/0032

a0098197 19 November 2001

Table 11. Set	verity of Dep	ression at Ba	seline
Variable	Reboxetine N=43	Fluoxetine N=42	P Value†
HAM-D total score			
No. of patients	43	42	
Mean ± SD	27.2 ± 5.4	28.3 ± 5.3	0.3440
Range	21 - 43	22 - 41	
HAM-D Item 1 score			
No. of patients	43	42	
Mean ± SD	2.5 ± 0.7	$\textbf{2.8}\pm\textbf{0.8}$	0.0423*
Range	1 - 4	1 - 4	
CGI Severity of Illness s	core		
No. of patients	43	42	
Mean ± SD	4.7 ± 0.9	4.9 ± 1.1	0.3016
Range	3 - 7	2 - 7	
SASS total score			
No. of patients	42	42	
Mean ± SD	26.8 ± 8.1	27.4 ± 7.9	0.7144
Range	7 - 45	15 - 44	

- --

 $p \leq 0.05$

t P values are based on a 1-way ANOVA with treatment as the main effect

Abbreviations: CGI = Clinical Global Impression, HAM-D = Hamilton Rating Scale for Depression, SASS = Social Adaptation Self-evaluation Scale Source: Table T8

7.1.5. Concomitant Medications and Other Therapies

7.1.5.1. Prior to the Study

At the screening evaluation, similar percentages of patients in each treatment group were taking at least one medication: 90.7% (39/43) of patients in the reboxetine group and 92.9%(39/42) of patients in the fluoxetine group. The medications that were taken most frequently (≥5% in any treatment group) were as follows: alprazolam, clonazepam, diclofenac sodium, estazolam, flurazepam, lorazepam, magnesium oxide, paracetamol, and zolpidem. Medications that were taken prior to the study are summarized in Table T9.1.

7.1.5.2. During the Treatment Period

Non-investigational medications were taken concomitantly with the study medication by similar percentages of patients in each treatment group: 93.0% (40/43) of patients in the reboxetine group and 97.6% (41/42) of patients in the fluoxetine group (Table T10.1). The medications that were taken most frequently ($\geq 5\%$ in any treatment group) were as follows: alprazolam, bisacodyl, bromazepam, calcium carbonate, clonazepam, diclofenac sodium, dimeticone, estazolam, flurazepam, flurazepam hydrochloride, lorazepam, hydrotalcite, magnesium hydroxide, magnesium oxide, oxazolam, paracetamol, zolpiclone, and zolpidem. Medications that were taken during the study are summarized in Table T10.1.

> Pharmacia — Company Confidential Page 46 of 342

PNU-155950E	a0098197
Study Report for M/2020/0032	19 November 2001

The concomitant use of psychotropic medications other than temazepam, lorazepam, flurazepam, estazolam, and oxazepam was not allowed during the study. The use of disallowed concomitant medications during the study is presented in Section 7.1.2, Protocol Deviations.

7.2. Dosage Information

7.2.1. Extent of Exposure

The mean daily doses of study medication are presented by visit in Table 12. These meandosing data suggest that most patients complied with the dosing regimens that were specified in the protocol for the reboxetine group (8 mg/day, weeks 1-4; 8-10 mg/day, weeks 5-8) and for the fluoxetine group (20 mg/day, weeks 1-4; 20-40 mg/day, weeks 5-8). Approximately 16% of the reboxetine-treated patients and 32% of the fluoxetine-treated patients who remained in the study were escalated during weeks 4 to 6 of the study (Appendix 3.5).

	Ret	ooxetine	Fluc	oxetine
Study Week	No. of Patients	Mean Dose* (mg/day)	No. of Patients	Mean Dose* (mg/day)
1	43	7.48	42	18.24
2	39	7.28	36	19.00
3	35	7.80	36	18.37
4	34	7.75	34	19.27
6	32	8.14	31	24.83
8	29	8.08	30	26.76
* Mean dail	v dose was ha	sed on the average	dose for all nat	ients who took

Table 12. Mean Daily Dose by Visit

 Mean daily dose was based on the average dose for all patients who took the study medication between the preceding visit and the specified visit.
 Source: Table T11

The majority of the patients in both treatment groups showed acceptable treatment compliance, defined as an overall drug intake of at least 80% of the prescribed amount. In the reboxetine group, unacceptable compliance was noted in 3 patients (patient nos. 211, 220, and 297), whose mean daily doses were <6 mg for at least 2 consecutive weeks. Likewise, in the fluoxetine group, unacceptable compliance was noted in 4 patients (patient nos. 203, 215, 232, and 259), whose mean daily doses were <16 mg for at least 2 consecutive weeks. Two additional fluoxetine-treated patients (patient nos. 223 and 289) who discontinued from the study after 1 week had mean daily doses of <16 mg during the 1 week when they were enrolled in the study.

Appendix 3.5 contains a listing of the mean daily dose for each patient.

PNU-155950E	a0098197
Study Report for M/2020/0032	19 November 2001

7.3. Efficacy Results

7.3.1. Data Sets Analyzed

Efficacy analyses were based on the population of ITT patients who had at least one postbaseline evaluation for the specified efficacy measure (eg, HAM-D, CGI). As discussed in Section 7.1.2.2, 2 separate analyses of the data from the HAM-D, CGI, and SASS scales were conducted: the first analysis included data for all visits (those conducted in the clinic or via telephone interviews) and the second analysis excluded the data that were collected during telephone interviews. The discussion of efficacy results in the following sections focuses on the results of the first analysis and briefly summarizes the results of the second analysis. The full results of both analyses are included in the Tables section.

7.3.2. Primary Efficacy Variable

7.3.2.1. Analysis of Data From All Visits

The mean change from baseline in the HAM-D total score was similar in the reboxetine and fluoxetine groups at each postbaseline evaluation in the LOCF analysis. For example, the mean change from baseline in the HAM-D total score was -8.18 in the reboxetine group and -7.35 in the fluoxetine group at day 14, -10.79 in the reboxetine group and -11.50 in the fluoxetine group at day 28, and -14.05 in the reboxetine group and -14.78 in the fluoxetine groups were statistically significant (Table 13).

At the end of the study (day 56), the difference between the treatment groups in the mean change from baseline in the LOCF analysis was 0.72 (lower limit of 90% CI, -2.19). This difference was not considered to be clinically significant because the difference was less than 2 points. Likewise, the difference was not considered to be statistically significant because the lower limit of the 90% CI was <0 (Table 13). These results indicate that the reboxetine and fluoxetine groups were comparable on the primary endpoint, the mean change from baseline in the HAM-D total score at day 56 in the LOCF analysis.

Consistent with the results of the LOCF analyses, no clinically or statistically significant differences were observed between the treatment groups in the OC analysis of the mean change from baseline in the HAM-D total score at each postbaseline evaluation (Table 13). At the end of the study (day 56), the mean change from baseline in the HAM-D total score was -16.57 in the reboxetine group and -17.10 in the fluoxetine group, based on the OC analysis.

Pharmacia — Company Confidential Page 48 of 342 PNU-155950E Study Report for M/2020/0032 a0098197 19 November 2001

		Table 1	13. N	3. Mean Change From Baseline in the HAM-D Total Score	hang	e Fron	1 Base	<u>eline ir</u>	I the I	-MAH-	D Tot	al Scor	e			
									Stud	Study Visit						
			Bas	Baseline	Day 7	y 7	Day 14	14	Day	Day 21	Day	Day 28	Day 42	42	Day 56	56
			L	Mean	z	X *	L	X *	n	*X	u	X *	c	X *	u	X *
LOCF	Mean	RBX	43	27.23	38	-5.53	38	-8.18	38	-9.34	38	-10.79	38	-13.34	38	-14.05
	Change	FLX	42	28.33	39	-6.54	40	-7.35	40	-8.93	40	40 -11.50	40	-13.60	40	-14.78
	Statistic	Difference†		:	1.01	31	<u> </u>	-0.83	Ģ	-0.42	0	0.71	0.26	56	0.72	Ŋ
		LL 90% CI		:	-0.65	65	ς̈́	-3.06	က်	-3.06	÷	-1.78	-2.52	52	-2.19	6
		P-Value‡		:	0.7117	117	0.3709	209	0.5631	631	0.8	0.8373	0.6875	375	0.9711	11
Observed	Mean	RBX	43	27.23	38	-5.53	37	-8.05	35	-9.63	34	-11.59	29	-16.00	28	-16.57
Cases	Change	FLX	42	28.33	39	-6.54	36	-7.81	34	-10.44	32	-13.47	31	-16.13	29	-17.10
	Statistic	Difference†		;	1.(1.01	-0	-0.25	0.8	0.81	-	1.88	0.13	e	0.53	e n
		LL 90% CI		:	-0.65	65	-2.	-2.58	<u>-</u> -	-1.97	Ģ	-0.60	-2.70	20	-2.43	1 3
		P-Value‡		:	0.7117	117	0.5938	938	0.9;	0.9367	0.4	0.4132	0.6411	t11	0.8785	.85
* Mean	change fro	Mean change from baseline value.	lue.													
† Mean	change in	Mean change in the reboxetine	group	group minus the mean change in the fluoxetine group.	he mea	an chang	je in th	e fluoxe	tine gro	oup.						
‡ P valu	es are bas	P values are based on a ANOVA Type III sum of squares, adjusting for investigator.	/A Typ	e III sum	n of squ	lares, ac	Jjusting) for inv∈	estigato	ŗ.						
Abbreviati	ons: ANO'	Abbreviations: ANOVA = analysis of variance, CI = confidence interval, FLX= fluoxetine, HAM-D = Hamilton Rating Scale for Depression,	of variá	ance, Cl	= confi	dence ir	nterval,	FLX= fl	uoxetin	ie, HAM	Η = O-I	amilton F	Rating 5	Scale fo	r Depre	ssion,
LL = lowe	⁻ limit, LOC	LL = lower limit, LOCF = last observation carried forward, RBX = reboxetine	vation	carried t	orward	I, RBX =	: rebox(etine								
Source:]	ables T12	Source: Tables T12.1, T12.2, T12.3, T12.4	.3, T1	2.4												

PNU-155950E	a0098197
Study Report for M/2020/0032	19 November 2001

7.3.2.2. Exclusion of Data From Telephone Interviews

When the analysis of the mean change from baseline in the HAM-D total score was repeated to exclude the data that were collected via telephone interviews, the results remained consistent with the results of the original analysis.

Excluding the data from the telephone interviews, the mean change from baseline in the HAM-D total score was similar in the reboxetine and fluoxetine groups at each postbaseline evaluation in the LOCF analysis. For example, the mean change from baseline in the HAM-D total score was -8.18 in the reboxetine group and -7.20 in the fluoxetine group at day 14, -10.71 in the reboxetine group and -11.50 in the fluoxetine group at day 28, and -13.63 in the reboxetine group and -14.78 in the fluoxetine group at day 56 (excluding data from telephone interviews). None of the differences between the reboxetine and fluoxetine groups were statistically significant (Tables T12.5, T12.6, T12.7, T12.8).

At the end of the study (day 56), the difference between the treatment groups in the mean change from baseline in the LOCF analysis (excluding data from telephone interviews) was 1.14 (lower limit of 90% CI, -1.76). As in the original analysis, the difference between the treatment groups was not considered to be either clinically significant (because the difference was <2) or statistically significant (because the lower limit of the 90% CI was <0).

7.3.3. Secondary Efficacy Variables

7.3.3.1. HAM-D Response Rate

7.3.3.1.1. Analysis of Data From All Visits

The HAM-D response rate was similar in the reboxetine and fluoxetine groups at the postbaseline evaluations in the LOCF analysis. For example, the HAM-D response rate was 26.3% in the reboxetine group and 17.5% in the fluoxetine group at day 14, 34.2% in the reboxetine group and 45.0% in the fluoxetine group at day 28, and 55.3% in the reboxetine group and 57.5% in the fluoxetine group at day 56. None of the differences between the reboxetine and fluoxetine groups were statistically significant (Table 14).

Consistent with the results of the LOCF analyses, the HAM-D response rate was similar in the reboxetine and fluoxetine groups in the OC analysis. None of the differences between the reboxetine and fluoxetine groups were statistically significant. At the end of the study (day 56), the HAM-D response rate was 67.9% in the reboxetine group and 65.5% in the fluoxetine group, based on the OC analysis (Table 14).

Pharmacia — Company Confidential Page 50 of 342

				aule 1			I able 14. HAM-D Kespulise" hale	Naut					
	Treatment						Study	Study Visit					
Type of		Day 7	y 7	Day	Day 14	Day	Day 21	Da	Day 28	Day	Day 42	Day	Day 56
Analysis	Statistic	2	%	۲	%	2	%	c	%	c	%	c	%
LOCF	RBX	ო	7.9	10	26.3	13	34.2	13	34.2	17	44.7	21	55.3
	FLX	с	7.7	2	17.5	12	30.0	18	45.0	12	52.5	23	57.5
	P-Value†	0.0	0.9821	0.3	0.3893	0.7	0.7615	0.3	0.3233	0.4	0.4009	0.6	0.6972
Observed RBX	RBX	ო	7.9	6	24.3	12	34.3	12	35.3	16	55.2	19	67.9
Cases	FLX	ო	7.7	2	19.4	12	35.3	17	53.1	61	61.3	19	65.5
	P-Value†	0.0	0.9821	0.6	0.6840	0.8	0.8242	0.1	0.1403	0.5	0.5465	36.0	0.9840
* Respor	Response was defined as a decrease of ≥50% in the 21-Item HAM-D total score versus baseline.	as a decr	ease of	≥50% in	the 21-It	em HAN	1-D total s	score ve	rsus base	eline.			
Abbreviati	F P values are based on a Cochran-Mantel-Haenszel test, adjusting for investigator Abbreviations: FLX= fluoxetine, HAM-D = Hamilton Rating Scale for Depression, LOCF = last observation carried forward, RBX Abbreviations: FLX= fluoxetine, HAM-D = Hamilton Rating Scale for Depression, LOCF = last observation carried forward, RBX Abbreviations: FLX= fluoxetine, HAM-D = Hamilton Rating Scale for Depression, LOCF = last observation carried forward, RBX Abbreviations: FLX= fluoxetine, HAM-D = Hamilton Rating Scale for Depression, LOCF = last observation Context of the second scale for Depression, LOCF = last observation Context of the second scale for Depression, LOCF = last observation Context of the second scale for Depression, LOCF = last observation Context of the second scale for Depression, LOCF = last observation Context of the second scale for Depression, LOCF = last observation Context of the second scale for Depression, LOCF = last observation Context of the second scale for Depression, LOCF = last observation Context of the second scale for Depression, LOCF = last observation Context of the second scale for Depression, LOCF = last observation Context of the second scale for Depression, LOCF = last observation Context of the second scale for Depression, LOCF = last observation Context of the second scale for Depression, LOCF = last observation Context of the second scale for Depression, LOCF = last observation Context of the second scale for Depression, LOCF = last observation Context of the second scale for Depression, LOCF = last observation Context of the second scale for Depression, LOCF = last observation Context of the second scale for Depression, LOCF = last observation Context of the second scale for Depression, LOCF = last observation Context of the second scale for Depression, LOCF = last observation Context of the second scale for Depression, LOCF = last observation Context of the second s	a Cochra etine, HA	n-Mantel	I-Haensz Hamilton	el test, a Rating S	djusting cale for	for invesi Depressi	tigator on, LOC	F = last c	bservati	ion carrie	a forwar	d, RBX
= reboxetine	ne)		-	×					

Table 14. HAM-D Resnonse* Rate

PNU-155950E

Study Report for M/2020/0032

Source: Tables T13.1, T13.2

Anhang: Dokumentation der Stellungnahmen zum Vorbericht A05-20C. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)

> a0098197 19 November 2001

PNU-155950E	a0098197
Study Report for M/2020/0032	19 November 2001

7.3.3.1.2. Exclusion of Data From Telephone Interviews

When the analysis of the HAM-D response rate was repeated to exclude the data that were collected via telephone interviews, the results remained consistent with the results of the original analysis. Excluding the data from the telephone interviews, the HAM-D response rate was 26.3% in the reboxetine group and 17.5% in the fluoxetine group at day 14, 34.2% in the reboxetine group and 45.0% in the fluoxetine group at day 28; and 55.3% in the reboxetine group and 57.5% in the fluoxetine group at day 56 in the LOCF analysis. None of the differences between the reboxetine and fluoxetine groups were statistically significant (Tables T13.3, T13.4).

7.3.3.2. HAM-D Remission Rate

7.3.3.2.1. Analysis of Data From All Visits

The HAM-D remission rate was similar in the reboxetine and fluoxetine groups at the postbaseline evaluations in the LOCF analysis. The HAM-D remission rate was 5.3% in the reboxetine group and 10.0% in the fluoxetine group at day 14, 15.8% in the reboxetine group and 27.5% in the fluoxetine group at day 28, and 36.8% in the reboxetine group and 40.0% in the fluoxetine group at day 56. None of the differences between the reboxetine and fluoxetine groups were statistically significant (Table 15).

Consistent with the results of the LOCF analyses, the HAM-D remission rate was similar in the reboxetine and fluoxetine groups in the OC analysis. None of the differences between the reboxetine and fluoxetine groups were statistically significant. At the end of the study (day 56), the HAM-D remission rate was 50.0% in the reboxetine group and 48.3% in the fluoxetine group, based on the OC analysis (Table 15).

			Ë	able 15	HAN.	1-D Re	Table 15. HAM-D Remission* Rate	n* Rate	Ъ				
	Treatment						Study	Study Visit					
Type of		Da	Day 7	Day	Day 14	Day	Day 21	Da	Day 28	Day	Day 42	Day 56	56
Analysis	Statistic	۲	%	L	%	_	%	c	%	c	%	c	%
LOCF	RBX	-	2.6	2	5.3	4	10.5	9	15.8	13	34.2	14	36.8
	FLX	۲	2.6	4	10.0	8	20.0	11	27.5	15	37.5	16	40.0
	P-Value†	6.0	0.9433	0.3	0.3952	0.1	0.1409	0.1	0.1164	0.5691	691	0.5929	929
Observed RBX	RBX	-	2.6	2	5.4	4	11.4	9	17.6	13	44.8	14	50.0
Cases	FLX	-	2.6	4	11.1	ω	23.5	10	31.3	14	45.2	14	48.3
	P-Value†	6.0	0.9433	0.3	0.3856	0.0	0.0789	0.0	0.0985	0.8097	260	0.9827	327
* Remiss	Remission was defined as a total score of ≤10 on the 21-Item HAM-D.	as a tota	l score o	f ≤10 on	the 21-It	em HAN	1-D.						
† P valu∈	· P values are based on a Cochran-Mantel-Haenszel test, adjusting for investigator	a Cochrai	n-Mantel	-Haensz	el test, a	djusting	for invest	tigator					
Abbreviati	Abbreviations: FLX= fluoxetine, HAM-D = Hamilton Rating Scale for Depression, LOCF = last observation carried forward, RBX	etine, HA	H = O-M	lamilton	Rating S	cale for	Depressi	on, LOC)F = last c	bservati	on carrie	d forwar	d, RBX
= reboxetine	ine												
Source: 7	Source: Tables T14.1, T14.2	4.2											

PNU-155950E Study Report for M/2020/0032

a0098197 19 November 2001

Anhang: Dokumentation der Stellungnahmen zum Vorbericht A05-20C. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)

PNU-155950E	a0098197
Study Report for M/2020/0032	19 November 2001

7.3.3.2.2. Exclusion of Data From Telephone Interviews

When the analysis of the HAM-D remission rate was repeated to exclude the data that were collected via telephone interviews, the results remained consistent with the results of the original analysis. Excluding the data from the telephone interviews, the HAM-D remission rate was 5.3% in the reboxetine group and 10.0% in the fluoxetine group at day 14, 15.8% in the reboxetine group and 27.5% in the fluoxetine group at day 28; and 34.2% in the reboxetine group and 40.0% in the fluoxetine group at day 56 in the LOCF analysis. None of the differences between the reboxetine and fluoxetine groups were statistically significant (Tables T14.3, T14.4).

7.3.3.3. CGI Severity of Illness

7.3.3.3.1. Analysis of Data From All Visits

The mean change from baseline in the CGI Severity of Illness score was similar in the reboxetine and fluoxetine groups at the postbaseline evaluations in the LOCF analysis. For example, the mean change from baseline in the CGI Severity of Illness score was -1.0 in the reboxetine group and -0.8 in the fluoxetine group at day 14, -1.4 in the reboxetine group and -1.5 in the fluoxetine group at day 28, and -2.0 in the reboxetine group and -2.1 in the fluoxetine group at day 56. None of the differences between the reboxetine and fluoxetine groups were statistically significant (Table 16).

Consistent with the results of the LOCF analyses, the mean change from baseline in the CGI Severity of Illness score was similar in the reboxetine and fluoxetine groups in the OC analysis. None of the differences between the reboxetine and fluoxetine groups were statistically significant. At the end of the study (day 56), the mean change from baseline in the CGI Severity of Illness score was -2.3 in both the reboxetine and fluoxetine groups, based on the OC analysis (Table 16).

Pharmacia — Company Confidential Page 54 of 342

	Table 16	S.	16. Mean Change From Baseline in the CGI Severity of Illness Score	nange	From	Basel	line in	the C	GI Se	verity	of Illn	less Sc	ore		
	Treatment							Stud	Study Visit						
Type of	•	Bas	Baseline	Day 7	17	Day 14	14	Day 21	21	Day 28	28	Day 42	42	Day 56	56
Analysis	Statistic	u	Mean	u	X *	L	X *	n	*X	c	X *	u	X *	L	Χ*
LOCF	RBX	43	4.7	38	-0.3	38	-1.0	38	-1.1	38	-1.4	38	-1.7	38	-2.0
	FLX	42	4.9	39	-0.6	40	-0.8	40	-1.2	40	-1.5	40	-1.7	40	-2.1
	P-Value†			0.6023	023	0.1509		0.6864	364	0.6814	314	0.3338	38	0.5303	803 103
Observed RBX	RBX	43	4.7	38	-0.3	37	-1.0	35	-1.1	34	-1.5	29	-2.0	28	-2.3
Cases	FLX	42	4.9	39	-0.6	36	-0.9	34	-1.4	32	-1.7	31	-2.0	29	-2.3
	P-Value†		:	0.6023	023	0.2158	158	0.9488	188	0.9894	394	0.3191	191	0.3900	00
* Mear P vali Abbreviati carried for Source: T	 Mean change from baseline value. P values are based on a ANOVA Type III sum of squares, adjusting for investigator. Abbreviations: ANOVA = analysis of variance, CGI = Clinical Global Impression, FLX= fluoxetine, LOCF = last observation carried forward, RBX = reboxetine Source: Tables T18.1, T18.2, T18.3, T18.4 	seline a AN nalysis oxetin 3.2, T1	baseline value. on a ANOVA Type III sum of squares, adjusting for investigator. analysis of variance, CGI = Clinical Global Impression, FLX= flu eboxetine 18.2, T18.3, T18.4	pe III si ance, C 3.4	um of sc GI = Cli	quares, nical G	adjustii ilobal Im	ng for ir Ipressic	ivestiga on, FLX	tor. = fluoxe	stine, LC	0CF = 16	ast obse	ervation	

PNU-155950E Study Report for M/2020/0032

a0098197 19 November 2001

PNU-155950E	a0098197
Study Report for M/2020/0032	19 November 2001

7.3.3.3.2. Exclusion of Data From Telephone Interviews

When the analysis of the mean change from baseline in the CGI Severity of Illness score was repeated to exclude the data that were collected via telephone interviews, the results remained consistent with the results of the original analysis. Excluding the data from the telephone interviews, the mean change from baseline in the CGI Severity of Illness score was -1.0 in the reboxetine group and -0.8 in the fluoxetine group at day 14, -1.4 in the reboxetine group and -1.5 in the fluoxetine group at day 28, and -1.9 in the reboxetine group and -2.1 in the fluoxetine group at day 56 in the LOCF analysis. None of the differences between the reboxetine and fluoxetine groups were statistically significant (Tables T18.5, T18.6, T18.7, and T18.8).

7.3.3.4. CGI Global Improvement Response Rate

7.3.3.4.1. Analysis of Data From All Visits

The CGI Global Improvement response rate was similar in the reboxetine and fluoxetine groups at the postbaseline evaluations in the LOCF analysis. For example, the CGI Global Improvement response rate was 34.2% in the reboxetine group and 35.0% in the fluoxetine group at day 14, 52.6% in the reboxetine group and 62.5% in the fluoxetine group at day 28, and 71.1% in the reboxetine group and 70.0% in the fluoxetine group at day 56. None of the differences between the reboxetine and fluoxetine groups were statistically significant (Table 17).

Consistent with the results of the LOCF analyses, the CGI Global Improvement response rate was similar in the reboxetine and fluoxetine groups in the OC analysis. None of the differences between the reboxetine and fluoxetine groups were statistically significant. At the end of the study (day 56), the CGI Global Improvement response rate was 85.7% in the reboxetine group and 79.3% in the fluoxetine group, based on the OC analysis (Table 17).

Pharmacia — Company Confidential Page 56 of 342

	Treatment					0	Study Visit	' Visit					
Type of	Group or	Da	Day 7	Day	Day 14	Day	Day 21	Da	Day 28	Day	Day 42	Day	Day 56
Analysis	Statistic	c	%	c	%	c	%	L	%	c	%	۲	%
LOCF	RBX	4	10.5	13	34.2	17	44.7	20	52.6	24	63.2	27	71.1
	FLX	10	25.6	14	35.0	18	45.0	25	62.5	28	70.0	28	70.0
	P-Value†	0.1	0.1072	0.9	0.9278	0.9	0.9319	0.4	0.4027	0.4	0.4593	0.9	0.9050
Observed RBX	RBX	4	10.5	12	32.4	16	45.7	19	55.9	22	75.9	24	85.7
Cases	FLX	10	25.6	13	36.1	17	50.0	23	71.9	25	80.6	23	79.3
	P-Value†	0.1	0.1072	0.8	0.8056	0.5	0.5476	0.1	0.1928	0.6	0.6355	0.6175	175
* Respoi Improv	Response was defined a Improvement scale.	as a scol	'e of ≤2 (correspo	onding to	"very m	as a score of ${\leq}2$ (corresponding to "very much improved" or "much improved") on the CGI Global	oved" or	"much in	nproveď) on the (CGI Glot	bal
† P value	+ P values are based on a Cochran-Mantel-Haenszel test, adjusting for investigator	a Cochra	n-Mantel	-Haensz	el test, a	djusting	for invest	tigator					
Abbreviat	Abbreviations: CGI = Clinical Global Impression, FLX= fluoxetine, LOCF = last observation carried forward, RBX = reboxetine	cal Glob;	al Impres	ssion, FL	.X= fluox(etine, LC)CF = las	t observ	ation car	ried forw	/ard, RB>	<= rebo>	ketine

F F

PNU-155950E Study Report for M/2020/0032

a0098197 19 November 2001

Source: Tables T17.1, T17.2

PNU-155950E	a0098197
Study Report for M/2020/0032	19 November 2001

The distribution of patients by category of CGI Global Improvement score at each visit is presented in Tables T16.1 (LOCF analysis) and T16.2 (OC analysis).

7.3.3.4.2. Exclusion of Data From Telephone Interviews

When the analysis of the CGI Global Improvement response rate was repeated to exclude the data that were collected via telephone interviews, the results remained consistent with the results of the original analysis. Excluding the data from the telephone interviews, the CGI Global Improvement response rate was 34.2% in the reboxetine group and 35.0% in the fluoxetine group at day 14, 52.6% in the reboxetine group and 62.5% in the fluoxetine group at day 28; and 71.1% in the reboxetine group and 70.0% in the fluoxetine group at day 56 in the LOCF analysis. None of the differences between the reboxetine and fluoxetine groups were statistically significant (Tables T17.3, T17.4).

The distribution of patients by category of CGI Global Improvement score at each visit (excluding data from telephone interviews) is presented in Tables T16.3 (LOCF analysis) and T16.4 (OC analysis).

7.3.3.5. Social Adaptation Self-evaluation Scale

7.3.3.5.1. Analysis of Data From All Visits

Statistically significant differences, in favor of reboxetine over fluoxetine, were observed in the mean change from baseline in the SASS total score at days 14, 21, and 56 in the LOCF analysis (Table 18). At the end of the study (day 56), the mean change from baseline in the SASS total score was 7.3 in the reboxetine group and 3.6 in the fluoxetine group (p=0.038), based on the LOCF analysis.

Consistent with the results of the LOCF analyses, statistically significant differences, in favor of reboxetine over fluoxetine, were observed in the OC analysis of the mean change from baseline in the SASS total score at days 14, 21, and 56 (Table 18). At the end of the study (day 56), the mean change from baseline in the SASS total score was 9.1 in the reboxetine group and 4.1 in the fluoxetine group (p=0.035), based on the OC analysis.

Pharmacia — Company Confidential Page 58 of 342

	Τč		TADIC TO. MICAII CHAIRSE FLUIII DASCHIE III UIC DADD TUUAI DCULC		lalige	TT OIII	Dabel		n an	T COT	ULAI D	core			
	Treatment							Stud	Study Visit						
Type of	Group or	Bas	Baseline	Day 7	y 7	Day 14	, 14	Day	Day 21	Day	Day 28	Day	Day 42	Day 56	56
Analysis	Statistic	۲	Mean	u	∔x	u	ЧX	u	ĻΧ	L	∔x	u	X†	u	X†
LOCF	RBX	42	26.8	38	1.8	38	3.0	38	4.0	38	4.6	38	6.1	38	7.3
	FLX	42	27.4	39	6.0	40	6.0	40	1.0	40	2.5	40	3.6	40	3.6
	P-Value‡		:	0.0	0.0558	0.03	0.0373*	30.0	0.0282*	0.1	0.1757	0.0	0.0776	0.0381*	81*
Observed RBX	RBX	42	26.8	38	1.8	37	3.1	34	4.4	34	5.0	29	8.0	28	9.1
Cases	FLX	42	27.4	39	0.9	36	0.4	34	1.0	32	2.5	31	3.8	29	4.1
	P-Value‡		;	0.0	0.0558	0.0325*	325*	0.04	0.0404*	0.1867	367	0.0731	731	0.0350*	50*
* p ≤ 0.05	.05														
† Mear	Mean change from baseline value.	seline	value.												
‡ P val	P values are based on a ANOVA Type III sum of squares, adjusting for investigator.	лаAN	IOVA Ty	oe III s	um of s	quares,	adjusti	ng for ir	rvestige	ttor.					
Abbreviati SASS = S Source: 7	Abbreviations: ANOVA = analysis of variance, FLX= fluoxetine, LOCF = last observation carried forward, RBX = reboxetine, SASS = Social Adaptation Self-evaluation Scale Source: Tables T20.1, T20.2, T20.3, T20.4	nalysi Self-e 0.2, T2	s of varia valuation 20.3, T20	ance, F n Scale).4	:LX= flu	oxetine	LOCF	= last c	bservat	ion car	ried for	vard, RI	3X = rel	boxetine	¢,

PNU-155950E Study Report for M/2020/0032 a0098197 19 November 2001

Anhang: Dokumentation der Stellungnahmen zum Vorbericht A05-20C. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)

PNU-155950E	a0098197
Study Report for M/2020/0032	19 November 2001

7.3.3.5.2. Exclusion of Data From Telephone Interviews

When the analysis of the mean change from baseline in the SASS total score was repeated to exclude the data that were collected via telephone interviews, the results remained consistent with the results of the original analysis. Statistically significant differences, in favor of reboxetine over fluoxetine, were observed in the mean change from baseline in the SASS total score at days 14, 21, 42, and 56 in both the LOCF and OC analyses (Tables T20.5, T20.6, T20.7, T20.8). At the end of the study (day 56), the mean change from baseline in the SASS total score (excluding data from telephone interviews) was 7.2 in the reboxetine group and 3.6 in the fluoxetine group (p=0.043) in the LOCF analysis.

7.3.4. Efficacy Conclusions

The results of this study demonstrate that the reboxetine and fluoxetine groups were comparable on the primary endpoint, the mean change from baseline in the HAM-D total score at day 56 in the LOCF analysis. Strong evidence of antidepressant activity was observed in both treatment groups, as demonstrated by mean change from baseline values in the HAM-D total score of -14.05 in the reboxetine group and -14.78 in the fluoxetine group (p=0.971). The difference between the treatment groups in the mean change values (0.72; lower limit of 90% CI, -2.19) was not considered to be either clinically significant (because the difference was <2) or statistically significant (because the lower limit of the 90% CI was <0).

As summarized in Table 19, the results on the primary endpoint were supported by results on the secondary measures of antidepressant efficacy. No statistically significant differences were observed between the treatment groups in the HAM-D response or remission rates, the CGI Global Improvement response rate, or the mean change from baseline in the CGI Severity of Illness score at day 56 in the LOCF analysis. Thus, the results of both the primary and secondary measures of antidepressant efficacy were consistent in demonstrating the comparable efficacy of reboxetine and fluoxetine for the treatment of patients with depression.

Pharmacia — Company Confidential Page 60 of 342

PNU-155950E	a0098197
Study Report for M/2020/0032	19 November 2001
Study Report for M/2020/0032	19 November 2001

Table 19. Summary of Antidepressant Efficacy Measures at Day 56 (LOCE Analysis)

Day 50 (LUCF Analy	ysis)	
Variable	Reboxetine N=43	Fluoxetine N=42	P Value
Primary Endpoint			
HAM-D total score, mean change from baseline	-14.05	-14.78	0.971
Secondary Endpoints			
% Responders or Remitters			
HAM-D Response	55.3	57.5	0.697
HAM-D Remission	36.8	40.0	0.593
CGI Global Improvement Response	71.1	70.0	0.905
Mean Change From Baseline			
CGI Severity of Illness	-2.0	-2.1	0.530
SASS total score	7.3	3.6	0.038*
*			

 $p \le 0.05$ (reboxetine superior to fluoxetine)

Abbreviations: CGI = Clinical Global Impression, HAM-D = Hamilton Rating Scale for Depression, SASS = Social Adaptation Self-evaluation Scale

Source: Tables T12.1, 12.2, 13.1, 14.1, 17.1, 18.1, 18.2, 20.1, 20.2

The results of the final secondary endpoint, the SASS total score, demonstrated that reboxetine is superior to fluoxetine for the improvement of social function. The mean change from baseline in the SASS total score was significantly greater in the reboxetine group (mean change of 7.3) than in the fluoxetine group (mean change of 3.6) at day 56 in the LOCF analysis (p=0.038).

Taken together, the results of this study clearly demonstrate the efficacy of reboxetine for the treatment of patients with depression.

7.4. Safety Results

7.4.1. Treatment-Emergent Adverse Events

7.4.1.1. Brief Summary

The percentages of patients who reported at least 1 TESS or at least 1 drug-related TESS were slightly higher in the reboxetine group (86.0% TESS and 79.1% drug-related TESS) than in the fluoxetine group (78.6% TESS and 66.7% drug-related TESS) (Table 20). However, the percentage of patients who discontinued due to TESS was slightly lower in the reboxetine group (5/43, 11.6%) than in the fluoxetine group (6/42, 14.3%). Serious TESS were reported in an equal number of patients (3 patients) in each treatment group.

Table 20 presents an overview of the percentage of patients in each treatment group who had at least one TESS (overall, drug-related, or serious) or who discontinued due to a TESS.

> Pharmacia — Company Confidential Page 61 of 342

PNU-155950E
Study Report for M/2020/0032

a0098197 19 November 2001

Table 20. Overall Summary of Treatment-Emergent Signs and Symptoms (TESS)

······································		_~~)		
		oxetine =43		xetine =42
	n	%	n	%
Patients with at least one TESS	37	86.0	33	78.6
Drug-related*	34	79.1	28	66.7
Serious	3	7.0	3	7.1
Patients who discontinued due to TESS	5	11.6	6	14.3
* TESS were considered to be drug-re	lated if in	the opinion	of the inve	stigator

TESS were considered to be drug-related if, in the opinion of the investigator, there was a reasonable possibility that the event was caused by the investigational medication.

Source: Tables T21, T24, T25.1, T26.1

7.4.1.2. All Treatment-Emergent Signs and Symptoms

7.4.1.2.1. Treatment-Emergent Signs and Symptoms by System Organ Class

The frequency of TESS is summarized by system organ class in Table 21. In both of the treatment groups, the most frequently reported TESS were events that were related to the gastrointestinal and nervous systems.

PNU-155950E Study Report for M/2020/0032 a0098197 19 November 2001

Table 21. Frequency of Treatment-Emergent Signs and
Symptoms (TESS) by System Organ Class

Symptoms (TESS) by	y Bysic	in Organ	U1455	
		oxetine N=43		oxetine I=42
MedDRA System Organ Class*	n	%	n	%
Patients with at least one TESS	37	86.0	33	78.6
Gastrointestinal disorders	28	65.1	23	54.8
Nervous system disorders	20	46.5	20	47.6
General disorders and administration site conditions	15	34.9	10	23.8
Cardiac disorders	12	27.9	2	4.8
Renal and urinary disorders	10	23.3	6	14.3
Vascular disorders	6	14.0	3	7.1
Skin & subcutaneous tissue disorders	4	9.3	3	7.1
Ear and labyrinth disorders	3	7.0		
Psychiatric disorders	3	7.0	6	14.3
Reproductive system and breast disorders	3	7.0	3	7.1
Respiratory, thoracic, and mediastinal disorders	3	7.0		
Investigations	2	4.7		
Blood and lymphatic system disorders	1	2.3		
Eye disorders	1	2.3	3	7.1
Hepato-biliary disorders	1	2.3		
Infections and infestations	1	2.3	1	2.4
Metabolism and nutrition disorders	1	2.3	2	4.8
Musculoskeletal, connective tissue, and bone disorders	1	2.3	3	7.1

Arranged in decreasing order of frequency based on the reboxetine group.
 No patients reported this event.

Source: Table T21

Table T21 summarizes the TESS by system organ class and treatment group. The patients who reported TESS are listed in Appendix 3.7.1 (by patient) and Appendix 3.7.2 (by system organ class and preferred term).

7.4.1.2.2. Treatment-Emergent Signs and Symptoms by Preferred Term

The TESS that were reported in at least 5% of the patients in any treatment group are summarized in Table 22.

PNU-155950E Study Report for M/2020/0032 a0098197 19 November 2001

Table 22. TESS Reported in ≥5% of Patients in Either Treatment Group

I reatment Group							
	Reb	oxetine	Flue	oxetine			
MedDRA System Organ Class/	1	N=43	Ν	=42			
Preferred Term*	n	%	n	%			
GASTROINTESTINAL DISORDERS							
Dry mouth	20	46.5	14	33.3			
Nausea	8	18.6	7	16.7			
Constipation	7	16.3	6	14.3			
Abdominal distension	1	2.3	3	7.1			
NERVOUS SYSTEM DISORDERS							
Hypoesthesia	9	20.9	1	2.4			
Dizziness (excluding vertigo)	5	11.6	6	14.3			
Paraesthesia NEC	4	9.3	2	4.8			
Tremor NEC	3	7.0	4	9.5			
Insomnia NEC	3	7.0	3	7.1			
Taste disturbance	3	7.0	1	2.4			
Headache NOS			5	11.9			
Somnolence			3	7.1			
GENERAL DISORDERS AND ADMIN	IISTRATI	ON SITE CC	NDITION	S			
Shivering	7	16.3	4	9.5			
Fatigue	5	11.6	5	11.9			
Feeling hot	3	7.0					
Chest pain NEC	1	2.3	3	7.1			
Feeling cold	1	2.3	3	7.1			
CARDIAČ DISORDERS	-						
Palpitations	7	16.3	2	4.8			
Tachycardia NOS	4	9.3					
RENAL AND URINARY DISORDERS	-						
Urinary retention	8	18.6	4	9.5			
VASCULAR DISORDERS							
Postural hypotension	6	14.0	2	4.8			
SKIN & SUBCUTANEOUS TISSUE D		1	-	_			
Sweating increased	3	7.0					
EAR AND LABYRINTH DISORDERS		-	-	_			
Vertigo NEC	3	7.0					

Arranged in decreasing order of frequency based on the reboxetine group.
 No patients reported this event.

Abbreviations: NEC = not elsewhere classified, NOS = not otherwise specified, TESS = treatment-emergent signs and symptoms

Source: Table T21

In the reboxetine group, the most frequently reported TESS (reported in at least 10% of patients) were dry mouth, nausea, constipation, hypoesthesia, dizziness, shivering, fatigue, palpitations, urinary retention, and postural hypotension.

In the fluoxetine group, the most frequently reported TESS (reported in at least 10% of patients) were dry mouth, nausea, constipation, dizziness, headache, and fatigue.

PNU-155950E	a0098197
Study Report for M/2020/0032	19 November 2001

7.4.1.2.3. Treatment-Emergent Signs and Symptoms by Maximum Intensity

The majority of TESS reported by patients in each treatment group were mild to moderate in intensity. Severe TESS were reported in 25.6% (11/43) of the patients in the reboxetine group and in 14.3% (6/42) of the patients in the fluoxetine group (Appendix 3.7.1). The TESS that were reported in at least 5% of the patients in any treatment group are summarized by maximum intensity in Table 23.

	эroup by	v Maximu	im Inter	isity		
	Reboxetine N=43				Fluoxetine N=42	
MedDRA System Organ		n (%)			n (%)	
Class/ Preferred Term*	Mild	Mod	Severe	Mild	Mod	Severe
GASTROINTESTINAL DISOF	DERS					
Dry mouth	4 (9.3%)	14 (32.6%)	2 (4.7%)	3 (7.1%)	10 (23.8%)	1 (2.4%)
Nausea	5 (11.6%)	2 (4.7%)	1 (2.3%)	6 (14.3%)	1 (2.4%)	
Constipation	3 (7.0%)	3 (7.0%)	1 (2.3%)	4 (9.5%)	2 (4.8%)	
Abdominal distension	1 (2.3%)			1 (2.4%)	1 (2.4%)	1 (2.4%)
NERVOUS SYSTEM DISORD	ERS					
Hypoesthesia	5 (11.6%)	4 (9.3%)		1 (2.4%)		
Dizziness (excluding vertigo)	2 (4.7%)	3 (7.0%)		4 (9.5%)	2 (4.8%)	
Paraesthesia NEC	1 (2.3%)	3 (7.0%)		1 (2.4%)	1 (2.4%)	
Tremor NEC	2 (4.7%)	1 (2.3%)		4 (9.5%)		
Insomnia NEC		3 (7.0%)		3 (7.1%)		
Taste disturbance	2 (4.7%)	1 (2.3%)		/		1 (2.4%)
Headache NOS				3 (7.1%)	2 (4.8%)	
Somnolence				3 (7.1%)		
GENERAL DISORDERS AND	ADMINIST	RATION SIT	E CONDITI	ONS		
Shivering		7 (16.3%)		1 (2.4%)	3 (7.1%)	
Fatigue	2 (4.7%)	3 (7.0%)		5 (11.9%)		
Feeling hot	2 (4.7%)	1 (2.3%)				
Chest pain NEC	1 (2.3%)			2 (4.8%)	1 (2.4%)	
Feeling cold	1 (2.3%)			3 (7.1%)		
CARDIAC DISORDERS						
Palpitations	5 (11.6%)	2 (4.7%)		2 (4.8%)		
Tachycardia NOS	4 (9.3%)					
RENAL AND URINARY DISORDERS						
Urinary retention	1 (2.3%)	7 (16.3%)		3 (7.1%)	1 (2.4%)	
VASCULAR DISORDERS		-				
Postural hypotension	2 (4.7%)	4 (9.3%)		1 (2.4%)	1 (2.4%)	
SKIN & SUBCUTANEOUS TI						
Sweating increased	2 (4.7%)	1 (2.3%)				
EAR AND LABYRINTH DISOR						
Vertigo NEC * Arranged in decreasing of	2 (4.7%)	1 (2.3%)				

Table 23. TESS Reported in ≥5% of Patients in Either Treatment Group by Maximum Intensity

Arranged in decreasing order of frequency based on the reboxetine group.
 No patients reported this event.

Abbreviations: NEC = not elsewhere classified, NOS = not otherwise specified, TESS = treatmentemergent signs and symptoms

Source: Table T22

Pharmacia — Company Confidential Page 65 of 342

PNU-155950E	a0098197
Study Report for M/2020/0032	19 November 2001

All TESS are summarized by maximum intensity in Table T22.

7.4.1.2.4. Treatment-Emergent Signs and Symptoms by Gender

The TESS that were reported in ≥ 2 male or female patients in either treatment group are summarized by gender in Table 24.

Treatment Group by Gender						
	Reboxetine n (%)		Fluoxetine n (%)			
MedDRA System Organ Class/ Preferred Term*	Male N=16	Female N=27	Male N=16	Female N=26		
Patients with at least one TESS	13 (81.3%)	24 (88.9%)	11 (68.8%)	22 (84.6%)		
GASTROINTESTINAL DISOR	DERS					
Dry mouth	8 (50.0%)	12 (44.4%)	6 (37.5%)	8 (30.8%)		
Nausea	4 (25.0%)	4 (14.8%)	2 (12.5%)	5 (19.2%)		
Constipation	2 (12.5%)	5 (18.5%)	(6 (23.1%)		
Sore throat NOS	/	2 (7.4%)				
Abdominal distension	1 (6.3%)			3 (11.5%)		
NERVOUS SYSTEM DISORD						
Hypoesthesia	5 (31.3%)	4 (14.8%)		1 (3.8%)		
Dizziness (exc vertigo)	1 (6.3%)	4 (14.8%)	1 (6.3%)	5 (19.2%)		
Paraesthesia NEC	2 (12.5%)	2 (7.4%)	1 (6.3%)	1 (3.8%)		
Tremor NEC	1 (6.3%)	2 (7.4%)	2 (12.5%)	2 (7.7%)		
Insomnia NEC	2 (12.5%)	1 (3.7%)	1 (6.3%)	2 (7.7%)		
Taste disturbance	2 (12.5%)	1 (3.7%)		1 (3.8%)		
Headache NOS				5 (19.2%)		
Somnolence			1 (6.3%)	2 (7.7%)		
GENERAL DISORDERS AND	ADMINISTRATIO	N SITE CONDITI	ONS			
Shivering	3 (18.8%)	4 (14.8%)	2 (12.5%)	2 (7.7%)		
Fatigue	1 (6.3%)	4 (14.8%)	1 (6.3%)	4 (15.4%)		
Feeling hot		3 (11.1%)				
Chest pain NEC	1 (6.3%)		1 (6.3%)	2 (7.7%)		
Feeling cold	1 (6.3%)		3 (18.8%)			
CARDIAC DISORDERS						
Palpitations	4 (25.0%)	3 (11.1%)		2 (7.7%)		
Tachycardia NOS	2 (12.5%)	2 (7.4%)				
RENAL AND URINARY DISOF	RDERS					
Urinary retention	4 (25.0%)	4 (14.8%)	3 (18.8%)	1 (3.8%)		
VASCULAR DISORDERS						
Postural hypotension	4 (25.0%)	2 (7.4%)	1 (6.3%)	1 (3.8%)		
SKIN & SUBCUTANEOUS TISSUE DISORDERS						
Sweating increased	2 (12.5%)	1 (3.7%)				
EAR AND LABYRINTH DISORDERS						
Vertigo NEC	1 (6.3%)	2 (7.4%)				
EYE DISORDERS						
Vision blurred		1 (3.7%)		2 (7.7%)		

Table 24. TESS Reported in ≥2 Male or Female Patients in Either Treatment Group by Gender

Pharmacia — Company Confidential Page 66 of 342

PNU-155950E	a0098197
Study Report for M/2020/0032	19 November 2001

Table 24. TESS Reported in ≥2 Male or Female Patients in Either Treatment Group by Gender

freument Group sy Genati						
	Reboxetine n (%)		Fluoxetine n (%)			
MedDRA System Organ Class/ Preferred Term*	Male N=16	Female N=27	Male N=16	Female N=26		
Patients with at least one TESS	13 (81.3%)	24 (88.9%)	11 (68.8%)	22 (84.6%)		
PSYCHIATRIC DISORDERS						
Hypomania	1 (6.3%)		2 (12.5%)			
METABOLISM AND NUTRITION DISORDERS						
Appetite decreased NOS		1 (3.7%)		2 (7.7%)		
MUSCULOSKELETAL, CONNECTIVE TISSUE AND BONE DISORDERS						
Back pain		1 (3.7%)		2 (7.7%)		
* A way was a line descention and an affine success to a set the vehaution averus						

Arranged in decreasing order of frequency based on the reboxetine group.
 No patients reported this event.

Abbreviations: NEC = not elsewhere classified, NOS = not otherwise specified, TESS = treatmentemergent signs and symptoms

Source: Table T23

Of the TESS that were reported in ≥ 2 male or female reboxetine-treated patients, sore throat, dizziness, fatigue, and feeling hot were reported at least 2 times more frequently (on a percentage basis) in the reboxetine-treated female patients than in the reboxetine-treated male patients, whereas hypoesthesia, insomnia, taste disturbance, palpitations, postural hypotension, and increased sweating were reported at least 2 times more frequently in the reboxetine-treated male patients than in the reboxetine-treated male patients.

Of the TESS that were reported in ≥ 2 male or female fluoxetine-treated patients, constipation, abdominal distension, dizziness, headache, fatigue, palpitations, blurred vision, decreased appetite, and back pain were reported at least 2 times more frequently (on a percentage basis) in the fluoxetine-treated female patients than in the fluoxetine-treated male patients, whereas feeling cold, urinary retention, and hypomania were reported at least 2 times more frequently in the fluoxetine-treated male patients than in the fluoxetine-treated female patients than in the fluoxetine-treated female patients.

All TESS are summarized by gender in Table T23.

7.4.1.3. Drug-Related Treatment-Emergent Signs and Symptoms

TESS that were judged by the investigators to have been caused by the study medication were reported in 79.1% (34/43) of reboxetine-treated patients and 66.7% (28/42) of fluoxetine-treated patients. The drug-related TESS that were reported in at least 5% of patients in any treatment group are summarized in Table 25.

Pharmacia — Company Confidential Page 67 of 342

PNU-155950E Study Report for M/2020/0032 a0098197 19 November 2001

Table 25. Drug-Related* TESS Reported in ≥5% of Patients in Either Treatment Group

I allents in Little	I IIca	ment Gr	oup			
MedDRA System Organ Class/	Reboxetine N=43			xetine =42		
Preferred Term [†]	n	%	n	~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~		
Patients with at least one	34	79.1	28	66.7		
drug-related TESS	54	79.1	20	00.7		
GASTROINTESTINAL DISORDERS						
	19	44.2	13	31.0		
Dry mouth	7		5			
Nausea		16.3	-	11.9		
	6	14.0	4	9.5		
NERVOUS SYSTEM DISORDERS	0	10.0	4	0.4		
Hypoesthesia	8	18.6	1	2.4		
Dizziness (exc vertigo)	4	9.3	5	11.9		
Paraesthesia NEC	4	9.3	2	4.8		
Taste disturbance	3	7.0	1	2.4		
Tremor NEC	1	2.3	3	7.1		
Somnolence			3	7.1		
GENERAL DISORDERS AND ADMIN						
Shivering	7	16.3	4	9.5		
Feeling hot	3	7.0				
Feeling cold	1	2.3	3	7.1		
CARDIAC DISORDERS						
Palpitations	5	11.6	1	2.4		
Tachycardia NOS	4	9.3				
RENAL AND URINARY DISORDERS						
Urinary retention	8	18.6	4	9.5		
VASCULAR DISORDERS						
Postural hypotension	5	11.6	1	2.4		
SKIN & SUBCUTANEOUS TISSUE D	ISORDER	S				
Sweating increased	3	7.0				
* ***						

TESS were considered to be drug-related if, in the opinion of the investigator, there was a reasonable possibility that the event was caused by the investigational medication.

Arranged in decreasing order of frequency based on the reboxetine group.
 No patients reported this event.

Abbreviations: NEC = not elsewhere classified, TESS = treatment-emergent signs and symptoms

Source: Table T24

In the reboxetine group, the most frequently reported drug-related TESS (reported in at least 10% of patients) were dry mouth, nausea, constipation, hypoesthesia, shivering, palpitations, urinary retention, and postural hypotension.

In the fluoxetine group, the most frequently reported drug-related TESS (reported in at least 10% of patients) were dry mouth, nausea, and dizziness.

All drug-related TESS are summarized by system organ class and preferred term in Table T24.

Pharmacia — Company Confidential Page 68 of 342

PNU-155950E	a0098197
Study Report for M/2020/0032	19 November 2001

7.4.2. Deaths, Serious Adverse Events, and Other Significant Adverse Events

7.4.2.1. Deaths

No deaths were reported during this study (Table T27.4).

7.4.2.2. Serious Treatment-Emergent Signs and Symptoms

Serious TESS were reported in an equal number of patients (3 patients) in both of the treatment groups. The frequency of patients who experienced serious TESS is summarized in Table 26. Narrative summaries for patients who experienced serious TESS are provided in Section 7.4.2.4.

Reboxetine Fluoxetine					
MedDRA System Organ Class/		l=43	N=42		
Preferred Term*	n	%	n	%	
Patients with at least one serious	3	7.0	3	7.1	
TESS					
GASTROINTESTINAL DISORDERS					
Appendicitis	1	2.3			
Hemorrhoids	1	2.3			
INVESTIGATIONS					
Alanine aminotransferase	1	2.3			
increased					
Aspartate aminotransferase	1	2.3			
increased					
PSYCHIATRIC DISORDERS					
Suicide attempt			2	4.8	
RENAL AND URINARY DISORDERS					
Calculus ureteric			1	2.4	

Table	26.	Frequency	of	Serious	TESS
Lanc	40.	ricquency	υı	DUITUUS	

Arranged in decreasing order of frequency based on the reboxetine group.
 No patients reported this event.

Abbreviations: TESS = treatment-emergent signs and symptoms Source: Table T26.1

Among the serious TESS that occurred during the study, 2 events (increased alanine aminotransferase [ALT] and increased aspartate aminotransferase [AST] in patient no. 297) were judged by the investigator to have been caused by the study medication. Narrative summaries for all patients who experienced serious TESS are provided in Section 7.4.2.4.

All serious TESS are summarized by system organ class and preferred term in Table T26.1. Patients who experienced serious TESS are listed in Tables T26.2 (by patient) and T26.3 (by system organ class and preferred term).

PNU-155950E	a0098197
Study Report for M/2020/0032	19 November 2001

7.4.2.3. Discontinuations Due to Treatment-Emergent Signs and Symptoms

The percentage of patients who discontinued treatment due to TESS was slightly lower in the reboxetine group (11.6%; 5/43) than in the fluoxetine group (14.3%; 6/42) group. The TESS that led to discontinuation of treatment are summarized in Table 27.

_			
Reboxetine N=43		Fluoxetine N=42	
%	n	%	
11.6	6	14.3	
2.3	2	4.8	
	2	4.8	
2.3			
2.3			
2.3			
2.3			
2.3			
	1	2.4	
RDERS			
	1	2.4	
		*43 N % n 11.6 6 2.3 2 2 2.3 2.3 2.3 2.3 2.3 2.3 2.3 2.3 2.3 1 1	

Table 27. Frequency of TESS That Led toDiscontinuation of Treatment

Arranged in decreasing order of frequency based on the reboxetine group.
 No patients reported this event.

Abbreviations: NOS = not otherwise specified, TESS = treatment-emergent signs and symptoms

Source: Table T25.1

Most of the TESS that led to discontinuation of treatment were nonserious in nature. Serious TESS led to discontinuation of treatment in 2.3% (1/43) of reboxetine-treated patients (increased levels of ALT and AST in patient no. 297) and in 4.8% (2/42) of fluoxetine-treated patients (suicide attempt in patient nos. 223 and 299) (Table T27.3). Narrative summaries for all patients who experienced serious TESS are provided in Section 7.4.2.4.

Patients who discontinued treatment due to TESS are listed in Tables T25.2 (by patient) and T25.3 (by system organ class and preferred term). Patients who discontinued treatment due to serious TESS are listed in Table T27.2 (by patient) and T27.3 (by system organ class and preferred term).

PNU-155950E	a0098197
Study Report for M/2020/0032	19 November 2001

7.4.2.4. Narrative Summaries

Narrative summaries for the patients who experienced serious TESS are presented below. Both the verbatim and MedDRA terms for each event are presented (MedDRA terms are shown in parentheses).

7.4.2.4.1. Reboxetine

Patient No.:	211
Investigator:	Ru-Band Lu (No. 47044)
Treatment:	Reboxetine, 8 mg daily
Event:	Acute appendicitis and pelvic inflammatory disease (Appendicitis)

This 51-year-old female patient (Tri-Service General Hospital, Taipei, Taiwan) developed acute appendicitis and pelvic inflammatory disease while enrolled in this clinical study. She had a 29-year history of depression. Other relevant medical history included treatment for a gastric ulcer approximately 2 years prior to enrollment in the study. The patient began treatment with reboxetine on 20 March 2001. On 19 April 2001, she developed acute appendicitis and pelvic inflammatory disease. She was hospitalized for an appendectomy on 21 April 2001, at which time her hemoglobin level was 12.1 g/dL and leukocyte count was 7,000/µL. At the time of the event, the patient was receiving concomitant treatment with scopolamine to relieve lower abdominal pain. She recovered from the event on 24 April 2001. Treatment with reboxetine was continued during the event. However, on 30 April 2001, the patient discontinued study medication because she refused to continue with the study. (Discontinuation was unrelated to the adverse event.) The investigator considered the adverse event to be unrelated to treatment with the study medication.

Patient No.:	235
Investigator:	Shih-Ku Lin (No. 44699)
Treatment:	Reboxetine, 8 mg daily
Event:	Hemorrhoid (Hemorrhoids)

This 43-year-old male patient (Taipei City Psychiatric Center, Taipei, Taiwan) experienced an exacerbation of hemorrhoids on 26 January 2001. He had a 5-year history of hemorrhoids and a 6-year history of depression. The patient began treatment with reboxetine on 15 December 2000. On 09 February 2001, he was hospitalized and underwent an operation for management of hemorrhoid exacerbation. The patient recovered from the event and operation. Treatment with reboxetine was continued during the hospitalization, and the patient completed the study. At the time of the event, the patient was receiving concomitant treatment with Serenal (oxazolam) and Inderal (propanolol) for anxiety, Eurodin (estazolam) and Mesyrel (trazodone) for sleep disturbance, and magnesium oxide as a laxative. The investigator considered the adverse event to be unrelated to treatment with the study medication.

> Pharmacia — Company Confidential Page 71 of 342

PNU-155950E	a0098197
Study Report for M/2020/0032	19 November 2001

Patient No.:	297
Investigator:	Nein-Mu Chiu (No. 44700)
Treatment:	Reboxetine, 8 mg daily
Event:	Hepatitis (Increased ALT, Increased AST)

This 53-year-old female patient (Chang-Gung Memorial Hospital Kaohsiung, Kaohsiung, Taiwan) suffered an acute exacerbation of hepatitis B. The patient's medical history showed that she had been a hepatitis carrier since childhood. Her liver function test results were borderline normal at the screen evaluation on 07 February 2001 (see table, below). The patient began treatment with reboxetine on 15 February 2001. On 22 March 2001 (day 28 of study treatment), the results of liver function tests showed elevated values for ALT and AST. The abnormal values were confirmed on 28 March 2001. On 01 April 2001, the study medication was discontinued due to the abnormal liver function values. On 05 April 2001, the patient was hospitalized due to poor appetite, weakness, and severe anxiety. She was discharged from the hospital on 07 April 2001. She was prescribed paroxetine for the treatment of MDD and intravenous fluids and vitamin complex (Silymarin, 150 mg) for the treatment of impaired liver function. A gastrointestinal specialist was consulted for further evaluation and management of the patient; the results of this follow-up evaluation were not reported. By 05 May 2001, the patient's liver function values had returned to levels similar to those observed at baseline. The investigator considered the adverse event to be unrelated to treatment with the study medication.

The results of liver function tests are shown below:

Date	AST (U/L)	ALT (U/L)
07 February 2001 (Screen)	50	64
22 March 2001 (Day 28)	140	187
28 March 2001 (Day 35)	197	243
05 April 2001	269	367
12 April 2001	200	331
16 April 2001	250	380
19 April 2001	241	422
24 April 2001	125	272
28 April 2001	67	148
02 May 2001	49	85
05 May 2001	51	69

7.4.2.4.2. Fluoxetine

Patient No.:	215
Investigator:	Ru-band Lu (No. 47044
Treatment:	Fluoxetine, 20 mg daily
Event:	Ureteral stone (Calculus ureteric)

This 53-year-old male patient (Tri-Service General Hospital, Taipei, Taiwan) developed a ureteral stone of the left ureter. He had a 2-year history of depression; no other relevant

Pharmacia — Company Confidential Page 72 of 342

PNU-155950E	a0098197
Study Report for M/2020/0032	19 November 2001

medical history was noted. The patient began treatment with fluoxetine on 24 March 2001. On 10 May 2001, he began suffering intermittent right flank pain. On 11 May 2001, he went to the emergency room, where the following laboratory test results were noted:

Assay	Value
Hematology	
Prothrombin time	11.9 s / 11.3 s
	(international normalized ratio, 1.09)
Activated partial	34.2 s / 30.1 s
thromboplastin time	
Hemoglobin	14 g/dL
White blood cell count	2820/μL
Platelets	148,000/μL
Chemistry	
Aspartate aminotransferase	19 IU/L
Alanine aminotransferase	15 IU/L
Blood urea nitrogen	18 mg/dL
Sodium	136 meq/L
Potassium	3.5 meq/L
Chloride	108 meq/L
Glucose	104 mg/dL
Urinalysis	
Red blood cells	2 - 4
White blood cells	0 - 1
Occult blood	2+
Protein	negative

The patient was admitted to the genitourinary ward on 12 May 2001. The ureteral stone was managed using ureter renography, retrograde pyelography, and catheterization. The patient recovered from the event on 15 May 2001 and was discharged under stable condition on the same day. He was advised to return for outpatient follow-up. Relevant concomitant medications included Ativan (lorazepam) for insomnia, Buscopan (hyoscine) for release pain, magnesium oxide for constipation, and gentamicin for infection. Treatment with the study drug was not interrupted, and the patient completed the study. The investigator considered the adverse event to be unrelated to treatment with the study medication.

Patient No.:	223
Investigator:	Ru-band Lu (No. 47044)
Treatment:	Fluoxetine, 20 mg daily
Event:	Suicide attempt (Suicide attempt)

This 20-year-old male patient (Tri-Service General Hospital, Taipei, Taiwan) attempted suicide by slashing his left wrist with a shaving blade due to "emotional dysphoria." He had a 2-year history of depression, with 2 previous episodes and no prior hospitalizations for depression. At baseline, his HAM-D Item-3 score was 2 (corresponding to "wishes he were dead or any thoughts of possible death to self"). He began treatment with fluoxetine on 16 April 2001. On 20 April 2001, he attempted suicide by inflicting a superficial slash wound (3 cm by 0.1 cm) to his left wrist. Medical management of the injury consisted of

Pharmacia — Company Confidential Page 73 of 342

PNU-155950E	a0098197
Study Report for M/2020/0032	19 November 2001

covering the laceration with dressing; no sutures were required. The date of recovery of the adverse event was noted as 27 April 2001. The patient was withdrawn from the study due to the suicide attempt; his last dose of study medication was taken on 19 April 2001. At the time of the event, the patient was receiving concomitant treatment with Dalmadorm (flurazepam) for sleep disturbance, Relax Gel (mephenesin) and Surgam (tiaprofenic acid) for muscle strain, and Tarivid (ofloxacin) otic solution for otitis media. The investigator considered the adverse event to be unrelated to treatment with the study medication.

Patient No.:	299
Investigator:	Nein-Mu Chiu (No. 44700)
Treatment:	Fluoxetine, 20 mg daily
Event:	Suicide attempt (Suicide attempt)

This 23-year-old female patient (Chang-Gung Memorial Hospital Kaohsiung, Kaohsiung, Taiwan) attempted suicide by ingesting an overdose of concomitant medications that had been prescribed to her while enrolled in this clinical study. She had experienced 1 previous episode of depression within the previous year. The current episode of depression began approximately 2 months prior to the patient's admission to the study. She had no prior hospitalizations for depression. She began treatment with fluoxetine on 03 May 2001. She developed progressively worsening depression, loss of interest, loss of energy, anhedonia, poor appetite, insomnia, feelings of worthlessness, anxiety, and social withdrawal. Her HAM-D Item-3 scores increased from 1 at baseline to 3 on day 14 (16 May 2001) (see table, below). On 17 May 2001, she attempted suicide by swallowing 8 lorazepam pills, 6 flurazepam pills, and 3 estazolam pills. She was taken to the emergency room by her husband and was then admitted to the acute care ward on 18 May 2001. The patient was withdrawn from the study due to the suicide attempt; her last dose of study medication was taken on 21 May 2001. At the time of the event, the patient was receiving concomitant treatment with estazolam (4 mg, as needed) and flurazepam (60 mg, in the evening [hs]) for insomnia and lorazepam (1 mg, twice daily) for anxiety. The investigator considered the adverse event to be unrelated to treatment with the study medication.

The patient's HAM-D Item-3 scores are shown below:

HAM-D Item 3		
Date	Score	Definition of Item-3 Score
02 May 2001 (Baseline)	1	"Feels life is not worth living"
10 May 2001 (Day 7)	2	"Wishes he were dead or any
		thoughts of possible death to self"
16 May 2001 (Day 14)	3	"Suicide ideas or gesture"

Pharmacia — Company Confidential Page 74 of 342

PNU-155950E	a0098197
Study Report for M/2020/0032	19 November 2001

7.4.3. Clinical Laboratory Evaluation

7.4.3.1. Hematology

7.4.3.1.1. Mean Changes From Baseline

Within the reboxetine group, no statistically significant changes from baseline were noted in the values for hemoglobin, leukocytes, platelets, or leukocyte differential (neutrophils, lymphocytes, monocytes, eosinophils, or basophils) at days 28 or 56 (Table T35). Statistically significant changes from baseline were noted in the values for erythrocytes (mean change of $0.086 \times 10^6/\mu$ L at day 28) and hematocrit (mean changes of 1.16% and 1.34% at days 28 and 56, respectively). However, the mean values remained within normal ranges, and none of the changes was considered to be clinically meaningful.

Within the fluoxetine group, no statistically significant changes from baseline were noted in the values for hemoglobin, hematocrit, erythrocytes, or monocytes at days 28 or 56. Statistically significant changes from baseline were noted in the values for platelets (mean change of $-17,971/\text{mm}^3$ at day 28) and leukocytes (mean changes of -0.77 and $-0.59 \times 10^3/\mu\text{L}$ at days 28 and 56, respectively). Statistically significant changes from baseline were also noted in the values for the following components of the leukocyte differential: segmented neutrophils (mean change of -0.60 and $-0.62 \times 10^3/\mu\text{L}$ at days 28 and 56, respectively), lymphocytes (mean change of 4.52% at day 56), eosinophils (mean changes of -0.054 and $-0.056 \times 10^3/\mu\text{L}$ at days 28 and 56, respectively), and basophils (mean change of $-0.005 \times 10^3/\mu\text{L}$ at day 56). However, the mean values remained within normal ranges, and none of the changes was considered to be clinically meaningful.

Table T35 provides summary statistics for each hematologic assay.

7.4.3.1.2. Values Outside of Predefined Normal Ranges

The majority of patients in each treatment group had postbaseline hematology values that were within the predefined normal ranges (Table T37). For all hematology assays except monocytes (absolute count), $\leq 25\%$ of patients had values outside of normal ranges. Monocyte (absolute count) values that were below the predefined normal limit ($<0.20x10^3/\mu$ l) were reported at day 56 in 43.5% (10/23) of the patients in the reboxetine group and 31.8% (7/22) of the patients in the fluoxetine group. However, monocyte (%) values were within normal limits in >96% of patients in each treatment group.

The frequency of patients who had hematology assay values outside of the predefined normal ranges is summarized in Table T37. Patients with postbaseline hematology assay values outside of the predefined normal ranges are listed in Appendix 3.8.4.

PNU-155950E	a0098197
Study Report for M/2020/0032	19 November 2001

7.4.3.2. Chemistries

7.4.3.2.1. Mean Changes From Baseline

Within the reboxetine group, no statistically significant changes from baseline were noted in the values for the majority of the serum chemistry assays, including alkaline phosphatase, ALT, AST, bilirubin, blood urea nitrogen, carbon dioxide, creatinine, glucose, potassium, sodium, or uric acid at days 28 or 56 (Table T36). A statistically significant change from baseline was noted in the value for chloride, which showed a mean change of -0.74 milliequivalents/L at day 28. However, the mean value remained within the normal range, and the change was not considered to be clinically meaningful.

Within the fluoxetine group, no statistically significant changes from baseline were noted in the values for the majority of the serum chemistry assays, including ALT, AST, bilirubin, blood urea nitrogen, chloride, potassium, sodium, or uric acid. Statistically significant changes from baseline were noted in the values for alkaline phosphatase (mean change of -4.71 U/L at day 28), carbon dioxide (mean change of -1.81 milliequivalents/L at day 56), creatinine (mean change of -0.047 mg/dL at day 56), and glucose (mean change of -5.41 mg/dL at day 56). However, the mean values remained within normal ranges, and none of the changes was considered to be clinically meaningful.

Table T36 provides summary statistics for each chemistry assay.

7.4.3.2.2. Values Outside of Predefined Normal Ranges

The majority of patients in each treatment group had postbaseline chemistry values that were within the predefined normal ranges (Table T38). Fewer than 18% of patients in any treatment group had postbaseline chemistry values that were outside of normal ranges.

The percentage of patients who had renal or liver function tests that were normal at baseline but were outside the predefined limits at day 56 are summarized in Table 28.

Pharmacia — Company Confidential Page 76 of 342

PNU-155950E	a0098197
Study Report for M/2020/0032	19 November 2001

Table 28. Patients With Values Outside the Predefined Normal Limits* for Liver or Renal Function Tests at Day 56

Duj 50				
	Reb	Reboxetine		oxetine
Test	N†	n (%)	N†	n (%)
Alkaline phosphatase	30	0 (0)	32	0 (0)
ALT	26	1 (3.8)	29	1 (3.4)
AST	28	2 (7.1)	28	0 (0)
Total bilirubin	29	2 (6.9)	31	1 (3.2)
BUN	29	1 (3.4)	31	1 (3.2)
Creatinine	29	0 (0)	31	1 (3.2)

Predefined normal limits: alkaline phosphatase 20-225 U/L, depending on sex and age of patient; total bilirubin 0.0-1.3 mg/dL; ALT 0-48 U/L; AST 0-55 U/L, depending on age of patient; creatinine 0.5-1.4 mg/dL; BUN 7-30 mg/dL, depending on age of patient.

No. of patients with a normal baseline value and at least one postbaseline measurement.

Abbreviations: ALT = alanine aminotransferase, AST = aspartate aminotransferase, BUN = blood urea nitrogen Source: Table T38

The elevated values for ALT and AST that were observed in patient no. 297 were reported as a serious TESS (see Section 7.4.2.4 for a narrative summary of this patient, who had a history of hepatitis B). With the exception of the elevated values that were reported in this patient, no clinically significant abnormal values (defined as values at least 3 times the upper limit of normal for ALT, AST, alkaline phosphatase, and bilirubin and creatinine values of at least 3.0 mg/dL) were observed.

The frequency of patients who had chemistry assay values that were outside of the predefined normal ranges is summarized in Table T38. Patients with postbaseline chemistry assay values outside of the predefined normal ranges are listed in Appendix 3.8.5.

7.4.4. Vital Signs

7.4.4.1. Mean Change From Baseline

Within both the reboxetine and fluoxetine groups, no statistically significant changes from baseline values for sitting systolic or diastolic blood pressure were observed at any postbaseline evaluation (Tables T28 and T29).

Statistically significant changes from baseline values for pulse rate were observed in both treatment groups at each postbaseline evaluation. These changes consisted of mean increases in pulse rate in the reboxetine group and mean decreases in pulse rate in the fluoxetine group. At the end of the study (day 56), the mean change from baseline pulse rate was +7.7 beats per minute in the reboxetine group and -6.4 beats per minute in the fluoxetine group (Table T30).

Pharmacia — Company Confidential Page 77 of 342

PNU-155950E	a0098197
Study Report for M/2020/0032	19 November 2001

Within the reboxetine group, no statistically significant changes from the baseline value for body weight were observed at any postbaseline evaluation. Within the fluoxetine group, statistically significant changes from the baseline value for body weight were observed at days 21, 42, and 56. At the end of the study (day 56), the mean change from baseline body weight was +0.1 kg in the reboxetine group and -1.4 kg in the fluoxetine group (Table T31).

7.4.4.2. Values Outside of Predefined Normal Ranges

The majority of patients in each treatment group had values for systolic or diastolic blood pressure or pulse rate that were within the predefined normal limits. The number of patients who had values that were outside of the predefined limits for systolic or diastolic blood pressure or pulse rate is summarized in Table 29.

Predefined Limits				
		Reboxetine N=43	Fluoxetine N=42	
Variable	Predefined Limit	n (%)*	n (%)*	
Systolic BP	≥180 mmHg			
	≤90 mmHg	7 (16.3)	3 (7.1)	
Diastolic BP	≥105 mmHg		1 (2.4)	
	≤50 mmHg	1 (2.4)	1 (2.4)	
Pulse	≥120 beats/min	2 (4.7)		
	≤50 beats/min			

Table 29. Patients With at Least One PostbaselineBlood Pressure or Pulse Rate Value Outside of thePredefined Limits

No patients had a value outside of the specified predefined limit
 * Percentages are based on the number of ITT patients.

Abbreviations: BP = blood pressure

Source: Tables T32, T33, T34 and Appendices 3.8.1, 3.8.2, 3.8.3

No clinically relevant differences were noted among the treatment groups in the frequency of patients who had vital sign values that were outside of the predefined limits. The majority of the patients in each treatment group who had a postbaseline vital sign that was outside of the predefined limit had only a single abnormal value.

The patients who had values that were outside of the predefined normal limits for vital signs are listed in Appendix 3.8.1 (systolic blood pressure), 3.8.2 (diastolic blood pressure) and 3.8.3 (pulse rate).

7.4.5. Electrocardiograms

7.4.5.1. ECG Abnormalities

The percentage of patients who had normal ECG findings at screen and abnormal ECG findings at day 56 was 27.6% (8/29) in the reboxetine group and 25.8% (8/31) in the

Pharmacia — Company Confidential Page 78 of 342

PNU-155950E	a0098197
Study Report for M/2020/0032	19 November 2001

fluoxetine group (Table T47). The majority of these abnormal ECG findings met the predefined criteria for "abnormal, but not clinically relevant" ECG findings, as defined by Cardiac Alert, the central laboratory that evaluated the ECGs. Only 1 patient (patient no. 279 in the fluoxetine group) had a normal ECG at baseline and an abnormal ECG finding at day 56 that was classified as clinically relevant. The ECG abnormality that was observed at day 56 was first degree atrioventricular block.

Patients who had abnormal postbaseline ECG findings at any visit are listed in Appendix 3.8.11.

7.4.5.2. Effects of Treatment on Heart Rate, PR, QRS, and QT Intervals

7.4.5.2.1. Mean Change from Baseline

Within the reboxetine group, statistically significant changes from baseline were noted in the values for PR and QT intervals at day 28 and in the values for PR and QRS intervals at day 56. However, for the PR and QT intervals, the mean change in the reboxetine group represented a decrease from baseline values (ie, no prolongation of the intervals was observed). In addition, the mean values at days 28 and 56 remained within the normal ranges for each of the intervals.

Within the fluoxetine group, no statistically significant changes from baseline were noted in the values for PR or QRS intervals at days 28 or 56. Statistically significant changes from baseline were noted in the values for QT interval at days 28 and 56.

Table 30 summarizes the mean changes from baseline values for ECG intervals at day 56.

	Day 50					
	Reboxetine N=29†			Fluoxetine N=31†		
	Baseline Mean	Mean Change	P Value‡	Baseline Mean	Mean Change	P Value‡
PR interval	162.4	-19.7	0.005*	169.7	-2.6	0.437
QRS interval	92.4	3.4	0.048*	93.2	1.0	0.557
QT interval	390.3	-12.4	0.070	391.0	13.5	0.025*
Heart rate	67.3	10.8	0.001*	65.5	-6.1	0.001

Table 30.	Mean Change From Baseline ECG Intervals at
	Dav 56

* p ≤ 0.05

Number of intent-to-treat patients with the specified ECG measurement at screen and at day 56.

Changes from baseline within each treatment group were tested using a paired t test.

Abbreviations: bpm = beats per minute, ECG = electrocardiogram, Source: Tables T39, T40, T41, T42

Statistically significant changes from baseline values for ECG heart rate were observed in both treatment groups at days 28 and 56. These changes consisted of mean increases in ECG heart rate in the reboxetine group and mean decreases in ECG heart rate in the fluoxetine

Pharmacia — Company Confidential Page 79 of 342

PNU-155950E	a0098197
Study Report for M/2020/0032	19 November 2001

group. At the end of the study (day 56), the mean change from baseline ECG heart rate was +10.8 beats per minute in the reboxetine group and -6.1 beats per minute in the fluoxetine group (Table 30).

Summary statistics for ECG intervals are provided in Tables T39 (heart rate), T40 (PR interval), T41 (QRS interval), and T42 (QT interval).

7.4.5.2.2. Values Outside of Predefined Limits

The majority of patients in each treatment group had values for ECG intervals that were within the predefined normal limits. The number of patients who had values that were outside of the predefined limits for heart rate, PR, QRS, or QT intervals is summarized in Table 31.

ECG Interval Outside of the Frederined Linits			
		Reboxetine N=43	Fluoxetine N=42
Variable	Predefined Limit	n (%)*	n (%)*
Heart Rate	≤50 beats/min	1 (2.3)	8 (19.0)
	≥120 beats/min		
PR Interval	≤110 msec	2 (4.6)	
	≥210 msec		
QRS Interval	≤30 msec		
	≥110 msec	1 (2.3)	2 (4.8)
QT Interval	≥470 msec	1 (2.3)	2 (4.8)

Table 31.	Patients With at Least One Postbaselin	ıe
ECG In	terval Outside of the Predefined Limits	

-- No patients had a value outside of the specified predefined limit

Percentages are based on the number of ITT patients.

Abbreviations: ECG = electrocardiogram

Source: Tables T43, T44, T45, T46 and Appendices 3.8.7-3.8.10

Patients who had postbaseline values that exceeded the predefined limits for ECG intervals are listed in Appendices 3.8.7 (ECG heart rate), 3.8.8 (PR interval), 3.8.9 (QRS interval), and 3.8.10 (QT interval). The PR interval at day 56 for patient no. 201 which is noted as 0.0 in Appendix 3.8.8 is actually a missing value for that timepoint.

7.4.6. Exposure in Utero

No patients became pregnant during the study. One patient (patient no. 298 in the reboxetine group) had a positive serum pregnancy test at screen and at baseline. This patient had been pregnant and had undergone a dilatation and curettage procedure approximately 1 month before the screening visit. Before the patient was enrolled in the study, an ultrasound examination was performed, which confirmed that the pregnancy had been terminated. Therefore, the elevated HCG value was attributed to the previously terminated pregnancy, and the patient was enrolled in the study. At the end of the study (week 8), the pregnancy test result was negative for this patient.

Pharmacia — Company Confidential Page 80 of 342

PNU-155950E	a0098197
Study Report for M/2020/0032	19 November 2001

7.4.7. Safety Conclusions

Treatment-emergent signs and symptoms were reported in 86.0% (37/43) of the reboxetine-treated patients and 78.6% (33/42) of the fluoxetine-treated patients. In the reboxetine group, the most frequently reported TESS (reported in at least 10% of patients) were dry mouth, nausea, constipation, hypoesthesia, dizziness, shivering, fatigue, palpitations, urinary retention, and postural hypotension. In the fluoxetine group, the most frequently reported TESS (reported in at least 10% of patients) were dry mouth, nausea, constipation, at least 10% of patients) were dry mouth, nausea, constipation, dizziness, headache, and fatigue.

Overall, the adverse-event profile that was observed for reboxetine in this study is consistent with the profile that was established in previous studies of reboxetine. Several adverse events, including hypoesthesia, shivering, palpitations, urinary retention, and postural hypotension, were reported at a higher frequency in this study than in the combined data from previous studies of reboxetine [23]. However, the relevance of these differences is not clear, due to the small sample size of this study.

Of the TESS that were reported in ≥ 2 male or female reboxetine-treated patients, sore throat, dizziness, fatigue, and feeling hot were reported at least 2 times more frequently (on a percentage basis) in the reboxetine-treated female patients than in the reboxetine-treated male patients, whereas hypoesthesia, insomnia, taste disturbance, palpitations, postural hypotension, and increased sweating were reported at least 2 times more frequently in the reboxetine-treated male patients than in the reboxetine-treated sweating were reported at least 2 times more frequently in the reboxetine-treated male patients than in the reboxetine-treated female patients.

Of the TESS that were reported in ≥ 2 male or female fluoxetine-treated patients, constipation, abdominal distension, dizziness, headache, fatigue, palpitations, blurred vision, decreased appetite, and back pain were reported at least 2 times more frequently (on a percentage basis) in the fluoxetine-treated female patients than in the fluoxetine-treated male patients, whereas feeling cold, urinary retention, and hypomania were reported at least 2 times more frequently in the fluoxetine-treated male patients than in the fluoxetine-treated female patients than in the fluoxetine-treated female patients.

No deaths were reported during this study. Serious TESS were reported in an equal number of patients (3 patients) in both of the treatment groups.

The percentage of patients who discontinued treatment due to TESS was slightly lower in the reboxetine group (11.6%; 5/43) than in the fluoxetine group (14.3%; 6/42) group. No individual events led to discontinuation of treatment in more than 1 reboxetine-treated patient. Hypomania and suicide attempt each led to discontinuation of treatment in 2 fluoxetine-treated patients.

The majority of patients in each treatment group had postbaseline hematology and chemistry values that were within the predefined normal ranges. No evidence of a treatment-related effect was noted on any hematologic or chemistry assay.

Pharmacia — Company Confidential Page 81 of 342

PNU-155950E	a0098197
Study Report for M/2020/0032	19 November 2001

No statistically significant changes from baseline values for sitting systolic or diastolic blood pressure were observed within either treatment group at any postbaseline evaluation. Likewise, no statistically significant changes from the baseline value for body weight were observed within the reboxetine group at any postbaseline evaluation. Within the fluoxetine group, statistically significant changes from the baseline value for body weight were observed at days 21, 42, and 56. At the end of the study (day 56), the mean change from baseline body weight was +0.1 kg in the reboxetine group and -1.4 kg in the fluoxetine group.

Statistically significant changes from baseline values for pulse rate and ECG heart rate were observed in both treatment groups at each postbaseline evaluation. At the end of the study (day 56), the mean change from baseline pulse rate was +7.7 beats per minute in the reboxetine group and -6.4 beats per minute in the fluoxetine group, whereas the mean change from baseline ECG heart rate was +10.8 beats per minute in the reboxetine group and -6.1 beats per minute in the fluoxetine group. However, only 2 reboxetine-treated patients had postbaseline values for pulse rate that were above the predefined limit (\geq 120 beats/min), and no reboxetine-treated patients had postbaseline values for ECG heart rate that were above the predefined limit (\geq 120 beats/min).

8. DISCUSSION AND OVERALL CONCLUSIONS

This phase III, multicenter, randomized, double-blind, active-controlled, parallel-group study was conducted in 85 patients aged 18 to 65 years who suffered from MDD without psychotic features, as diagnosed using criteria defined by DSM-IV. The primary objective of this study was to compare the antidepressant efficacy of reboxetine (administered at a dose of 8 to 10 mg/day for 8 weeks) with that of fluoxetine (administered at a dose of 20 to 40 mg/day for 8 weeks), as determined by the change from baseline in the 21-Item HAM-D total score at the last assessment in patients suffering from MDD.

A total of 85 patients were enrolled in the study and were randomized to receive treatment with reboxetine (43 patients) or fluoxetine (42 patients). All of the randomized patients received at least 1 dose of study medication. Therefore, the ITT population includes 43 reboxetine-treated patients and 42 fluoxetine-treated patients.

The patients in the study ranged in age from 19 to 64 years. All of the patients were Asian, and the majority (>60%) of the patients were female. No statistically significant differences were noted between the treatment groups in the severity of depression at baseline, as judged by the mean total scores for the HAM-D, the CGI Severity of Illness, or the SASS.

The results of this study demonstrate that the reboxetine and fluoxetine groups were comparable on the primary endpoint, the mean change from baseline in the HAM-D total score at day 56 in the LOCF analysis. Strong evidence of antidepressant activity was observed in both treatment groups, as demonstrated by mean change from baseline values in the HAM-D total score of -14.05 in the reboxetine group and -14.78 in the fluoxetine group (p=0.971). The difference between the treatment groups in the mean change values (0.72; Pharmacia — Company Confidential

Page 82 of 342

PNU-155950E	a0098197
Study Report for M/2020/0032	19 November 2001

lower limit of 90% CI, -2.19) was not considered to be either clinically significant (because the difference was <2) or statistically significant (because the lower limit of the 90% CI was <0).

As summarized in Table 32, the results on the primary endpoint were supported by results on the secondary measures of antidepressant efficacy. No statistically significant differences were observed between the treatment groups in the HAM-D response or remission rates, the CGI Global Improvement response rate, or the mean change from baseline in the CGI Severity of Illness score at day 56 in the LOCF analysis. Thus, the results of both the primary and secondary measures of antidepressant efficacy were consistent in demonstrating the comparable efficacy of reboxetine and fluoxetine for the treatment of patients with depression.

Table 32. Summary of Antidepressant Efficacy Measures atDay 56 (LOCF Analysis)

Variable	Reboxetine N=43	Fluoxetine N=42	P Value
Primary Endpoint			
HAM-D total score, mean change from baseline	-14.05	-14.78	0.971
Secondary Endpoints			
% Responders or Remitters			
HAM-D Response	55.3	57.5	0.697
HAM-D Remission	36.8	40.0	0.593
CGI Global Improvement	71.1	70.0	0.905
Response			
Mean Change From Baseline			
CGI Severity of Illness	-2.0	-2.1	0.530
SASS total score	7.3	3.6	0.038*

 $p \le 0.05$ (reboxetine superior to fluoxetine)

Abbreviations: CGI = Clinical Global Impression, HAM-D = Hamilton Rating Scale for Depression, SASS = Social Adaptation Self-evaluation Scale Source: Tables T12.1, 12.2, 13.1, 14.1, 17.1, 18.1, 18.2, 20.1, 20.2

The results of the final secondary endpoint, the SASS total score, demonstrated that reboxetine is superior to fluoxetine for the improvement of social function. The mean change from baseline in the SASS total score was significantly greater in the reboxetine group (mean change of 7.3) than in the fluoxetine group (mean change of 3.6) at day 56 in the LOCF analysis (p=0.038).

Treatment-emergent signs and symptoms were reported in 86.0% (37/43) of the reboxetine-treated patients and 78.6% (33/42) of the fluoxetine-treated patients. In the reboxetine group, the most frequently reported TESS (reported in at least 10% of patients) were dry mouth, nausea, constipation, hypoesthesia, dizziness, shivering, fatigue, palpitations, urinary retention, and postural hypotension. In the fluoxetine group, the most frequently reported TESS (reported in at least 10% of patients) were dry mouth, nausea,

Pharmacia — Company Confidential Page 83 of 342

PNU-155950E	a0098197
Study Report for M/2020/0032	19 November 2001

constipation, dizziness, headache, and fatigue. The majority of TESS that were reported by patients in each treatment group were mild to moderate in intensity.

Overall, the adverse-event profile that was observed for reboxetine in this study is consistent with the profile that was established in previous studies of reboxetine. Several adverse events, including hypoesthesia, shivering, palpitations, urinary retention, and postural hypotension, were reported at a higher frequency in this study than in the combined data from previous studies of reboxetine [23]. However, the relevance of these differences is not clear, due to the small sample size of this study.

No deaths were reported during this study. Serious TESS were reported in an equal number of patients (3 patients) in both of the treatment groups.

The percentage of patients who discontinued treatment due to TESS was slightly lower in the reboxetine group (11.6%; 5/43) than in the fluoxetine group (14.3%; 6/42) group. No individual events led to discontinuation of treatment in more than 1 reboxetine-treated patient. Hypomania and suicide attempt each led to discontinuation of treatment in 2 fluoxetine-treated patients.

The majority of patients in each treatment group had postbaseline hematology and chemistry values that were within the predefined normal ranges. No evidence of a treatment-related effect was noted on any hematologic or chemistry assay.

No statistically significant changes from baseline values for sitting systolic or diastolic blood pressure were observed within either treatment group at any postbaseline evaluation.

Statistically significant changes from baseline values for pulse rate and ECG heart rate were observed in both treatment groups at each postbaseline evaluation. At the end of the study (day 56), the mean change from baseline pulse rate was +7.7 beats per minute in the reboxetine group and -6.4 beats per minute in the fluoxetine group, whereas the mean change from baseline ECG heart rate was +10.8 beats per minute in the reboxetine group and -6.1 beats per minute in the fluoxetine group. However, only 2 reboxetine-treated patients had postbaseline values for pulse rate that were above the predefined limit (\geq 120 beats/min), and no reboxetine-treated patients had postbaseline values for ECG heart rate that were above the predefined limit (\geq 120 beats/min).

In conclusion, this phase III, multicenter, randomized, double-blind, active-controlled, parallel-group study demonstrated that the reboxetine and fluoxetine groups were comparable on the primary endpoint, the mean change from baseline in the HAM-D total score at day 56 in the ITT patient population. Overall, the adverse-event profile that was observed for reboxetine in this study is consistent with the profile that was established in previous studies of reboxetine. Several adverse events, including hypoesthesia, shivering, palpitations, urinary retention, and postural hypotension, were reported at a higher frequency in this study than in the combined data from previous studies of reboxetine [23]. However, the relevance

Pharmacia — Company Confidential Page 84 of 342

PNU-155950E	a0098197
Study Report for M/2020/0032	19 November 2001

of these differences is not clear, due to the small sample size of this study. No new safety concerns associated with the use of reboxetine were identified.

9. ACKNOWLEDGMENTS

The authors thank the following people for their contributions to the conduct of the study or to the preparation of the study report: Sharon S. Chang (Market Company Taiwan), Timothy D. Holt (Clinical Reporting Systems), Alice Huang (Market Company Taiwan), Jessica Lin (Market Company Taiwan), Patricia A. Smanik (Medical Writing), and Louise A. Wilson (Clinical Data Integration).

PNU-155950E	a0098197
Study Report for M/2020/0032	19 November 2001

10. REFERENCES LIST

- 1. Merikangas KR, Kupfer DJ. Mood disorders: Genetic aspects. In: Kaplan HI, Sadock BJ, eds. Comprehensive Textbook of Psychiatry. 6th ed. Baltimore, MD: Williams & Wilkins; 1995:1102-1116.
- 2. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 4th ed. Washington, DC, American Psychiatric Association, 1994.
- 3. Post RM. Mood Disorders: Somatic treatment. In: Kaplan HI, Sadock BJ, eds. Comprehensive Textbook of Psychiatry. 6th ed. Baltimore, MD: Williams & Wilkins; 1995:1152-1178.
- 4. Nierenberg A, Wright EC. Evolution of remission as the new standard in the treatment of depression. J Clin Psychiatry 1999;60(suppl 22):7-11.
- 5. Elkin I, Shea MT, Watkins JT, Sotsky SM, Collins JF, Glass DR, et al. National Institute of Mental Health Treatment of Depression Collaborative Research Program. General effectiveness of treatments. Arch Gen Psychiatry 1989;46(11):971-82.
- 6. Anderson IM, Tomenson BM. Treatment discontinuation with selective serotonin reuptake inhibitors compared with tricyclic antidepressants: a meta-analysis. Br Med J 1995;310(b992):1433-88.
- Montgomery SA, Henry J, McDonald G, Dinan T, Lader M, Hindmarch I, et al. Selective serotonin reuptake inhibitors: meta-analysis of discontinuation rates. Int Clin Psychopharmaco 1994;9(1):47-53.
- 8. Song F, Freemantle N, Sheldon TA, House A, Watson P, Long A, Mason J. Selective serotonin reuptake inhibitors: Meta-analysis of efficacy and acceptability. Br Med J 1993(13);306(6879):683-7.
- 9. Montgomery SA. Reboxetine: additional benefits to the depressed patient. J Psychopharmacol 1997;11(suppl 4):S9-15.
- 10. Healy D, McMonagle T. The enhancement of social functioning as a therapeutic principle in the management of depression. J Psychopharmacol 1997;11(suppl 4):S25-31.
- 11. Schildkraut JJ. The catecholamine hypothesis of affective disorders: a review of supporting evidence. Am J Psychiatry 1965;122(5):509-22.
- 12. Wong EH, Sonders MS, Amara SG, Tinholt PM, Piercey MF, Hoffmann WP, et al. Reboxetine: a pharmacologically potent, selective, and specific norepinephrine reuptake inhibitor. Biol Psychiatry 2000;47(9):818-29.

Pharmacia — Company Confidential Page 86 of 342

PNU-155950E	a0098197
Study Report for M/2020/0032	19 November 2001

- 13. Tatsumi M, Groshan K, Blakely RD, Richelson E. Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol 1997;340(2-3):249-58.
- 14. Dubini A, Ban TA, Money LC. Phase II controlled study of the activity and tolerability of reboxetine in comparison with placebo and desipramine in patients hospitalised for major depressive Disorder. Internal Report FCE 20124/702I, February 1991.
- 15. Ban TA, Dubini A,Giorgetti C, Petroccione A, Andreoli V, Caillard V, et al. Multicentre, multinational double blind study of the activity and tolerability of reboxetine versus fluoxetine and placebo in patients suffering from Major Depressive Episodes. Internal Report 9550080, December 1995.
- Brown MT, Brinkman SA, Reisner JK, Rowland CR. Reboxetine, placebo, and paroxetine comparison in patients with major depressive disorder (Protocol M/2020/0047). Pharmacia & Upjohn Study Report a0080877, 3 November 2000 (amended 6 February 2001).
- Ban TA, Morey LC, Fjetland OK, Dubini A. Phase II placebo-controlled clinical study with reboxetine in major depression. Farmitalia Carlo Erba Internal Report FCE 201124/706i, November 1993.
- Ban TA, Dubini A, Petroccione A, Castiglioni R, Gazner P, Mehilane L, et al. Multicentre, multinational double-blind study of the activity and tolerability of Reboxetine versus placebo in the continuation therapy of major depressive episodes. Pharmacia Internal Report 9550077, December 1995.
- Bosc M, Dubini A, Polin V. Development and validation of a social functioning scale, the Social Adaptation Self-Evaluation Scale. European Neuropsychopharmacology 1997;7(suppl 1):S57-70 (discussion, S71-73).
- 20. Prozac (fluoxetine hydrochloride) [package insert]. Indianapolis, IN: Eli Lilly and Company; 2001.
- 21. Hamilton M. Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 1967;6(4):278-96.
- Guy W. ECDEU assessment manual for psychopharmacology, Revised (DHEW Publication No. ADM. 76-338). Washington, DC: US Government Printing Office, 1976
- 23. New Drug Application 20-960 (Reboxetine mesylate). 2000 Safety Update Report. Pharmacia & Upjohn Document No. a0081901.

Pharmacia — Company Confidential Page 87 of 342